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ABSTRACT OF DISSERTATION

THE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS-MYOCARDIAL INFARCTION ASSOCIATION:
AN INVESTIGATION OF KENTUCKY MEDICAID PRESCRIPTION CLAIMS
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used
medications globally. There are generally two types: selective (COX-2) and traditional NSAIDs
(COX-1). They are primarily used for the treatment of pain. They gained attention after a study
about their basic mechanisms highlighted their toxicity.
Several studies have reported an association between NSAIDs and risk of myocardial
infarction (MI). However, the direction of the relationship is not conclusive. Further studies are
needed to ascertain the direction of this relationship and evaluate the present situation with
available drugs. Due to the seriousness of cardiovascular diseases as one of the leading cause of
death, continuous monitoring of the NSAIDs-MI association is needed.
The purpose of this dissertation was to investigate the association between NSAIDs and
MI in a younger (30-64 years) Kentucky Medicaid population with a 12 year window of data. The
three specific aims were: (1) to understand the characteristics of the Kentucky Medicaid
population with respect to NSAID use: (2) to evaluate the NSAID-MI relationship with a 12 year
follow-up in a young heavily-burdened population for cardiovascular diseases: and (3) to
investigate the MI risk of meloxicam, celecoxib and naproxen compared to no exposure.
A retrospective study was conducted employing data from January 1st 2000 and
December 31st 2012. The data comprised demographic, prescription and medical files. Within
this cohort, a nested case control study was conducted. Cases of MI were matched to four
controls on race and gender.
The results suggested that exposure to COX 2 presented an increased adjusted risk for
MI (1.138(0.983, 1.318)). However, this risk was significantly increased for COX-2 only users
compared to COX-1 only users (1.221 (1.03, 1.485)) and 30-40 year olds (1.600 (1.082, 2.367)).
Meloxicam, celecoxib and naproxen compared to no exposure showed meloxicam presented a
non-significant different risk for MI (1.26 (0.98, 1.63)) and celecoxib presented a significantly
increased risk for MI (1.52 (1.26, 1.82)).

This study considered pattern of use in determining continuous usage by looking at both
continuous and sporadic users of NSAIDs and also considered patient switching patterns
between classes of NSAIDs.
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Chapter One
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used
medications globally (Bombardier et al., 2000). There are generally two types categorized based
on their ability to inhibit the cyclooxygenase (COX) enzymes. They are selective (COX-2) and
traditional NSAIDs (COX-1)(Al-Saeed, 2011). They are primarily used for the treatment of pain.
They gained attention after a study about their basic mechanisms shed light on their toxicity
(Catella-Lawson et al., 1999). This relationship was strengthened in findings that emerged in
clinical trials and observational studies. The Vioxx Gastrointestinal Outcomes Research (VIGOR),
a clinical trial designed to examine gastrointestinal (GI) toxicity of refocoxib and naproxen in
patients with rheumatoid arthritis, found a higher incidence of myocardial infarction (MI) in
patients in the refocoxib group compared with those in the naproxen group (Bombardier et al.,
2000). Several pharmaco-epidemiologic studies confirmed and quantified these effects using
large linked databases in different countries (Garcia Rodriguez, Varas-Lorenzo, Maguire, &
Gonzalez-Perez, 2004; Daniel H Solomon et al., 2004).
NSAIDs inhibit the COX enzyme which is the first step in converting arachidonic acid to
prostaglandins, thromboxane and prostacyclin (Catella-Lawson et al., 1999). The COX enzyme
exists in two forms- COX-1 and COX-2. COX-1 produces prostaglandins responsible for
homeostatic functions such as platelet aggregation and gastric mucosa. COX-2 produces
prostaglandins that mediate pain and inflammation. The inhibition of COX-1 causes bleeding and
the inhibition of COX-2 suppresses prostacyclin which reacts with thromboxane for homeostatic
balance (Graham, 2006).
Several studies found an association between exposure to NSAIDs in general and risk of
MI. However, the direction of the relationship was not conclusive (Bombardier et al., 2000;
1

Silverstein et al., 2000; Daniel H Solomon et al., 2004; S. D. Solomon et al., 2005). The
Bombardier et al study found a lower incidence of MI among patients in the naproxen group
when compared to those in the rofecoxib group (relative risk (RR) = 0.2 [0.1, 0.7]). The
Silverstein et al study found no difference in the incidence of cardiovascular events in general
when celecoxib was compared to other NSAIDs. However, the event rates for this study were
very low. The Solomon et al study found an increase in death from cardiovascular diseases with
use of celecoxib when compared to placebo (hazard ratio (HR) =3.4[1.4, 7.8]).
In October 2004, rofecoxib was withdrawn from the market after a randomized placebocontrolled trial found it increased the rate of cardiovascular events in higher doses (Antman,
DeMets, & Loscalzo, 2005; Bresalier et al., 2005). Valdecoxib was removed in 2005 due to
concerns about increased risk of cardiovascular disease and stroke (Antman et al., 2005). Since
these removals, other generic NSAIDs have been developed and marketed with varying degrees
of study for adverse health effects (McGettigan & Henry, 2011). Additionally, some of these
drugs (like meloxicam) have been studied less due to small numbers of adverse health events
and population sizes.
Celecoxib is the only coxib that is still on the United States (US) market. While it is a
certified COX-2 its effect on cardiovascular risk varies across the literature. It was one of the
most widely prescribed NSAIDs in the US, has been in the market longer and has the largest
body of evidence of use. Meloxicam, is less studied compared to other commonly used NSAIDs
and has been hypothesized to have COX-2 tendencies even though it is classified as a COX-1
(McGettigan & Henry, 2011). In the Kentucky Medicaid population, it is observed that there is an
increased prescription of meloxicam especially after the removal of rofecoxib and valdecoxib
from the US market. This phenomenon was seen elsewhere(Barozzi & Tett, 2007). Naproxen is
one of the most prescribed NSAIDs worldwide and the safest NSAID based on the literature
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(Patrono & Baigent, 2014). It is a certified COX-1 and has consistently shown reduced risk for
cardiovascular adverse events when compared to other NSAIDs.
Due to the seriousness of cardiovascular diseases, continuous monitoring of the NSAIDsMI association is needed. Especially since cardiovascular diseases have been identified as one of
the leading causes of death worldwide (Alwan, 2011). Since the removal of rofecoxib and
valdecoxib from the US market, few studies have assessed this association for the remaining
NSAIDs on the market. Furthermore, observational studies are needed to buttress the body of
knowledge and give an update on the NSAID-MI association. They have the added value of
providing post-market surveillance in the study of this association. This study will examine this
association using 12 years of current available data with a potential longer follow-up. The
Kentucky Medicaid data used for this study provides comprehensive prescription information
for the subjects. A less controlled real world population would be optimal for this analysis as it
represents subjects taking the medication post-marketing with all the nuances involved. This
study is conducted using a real-world post-market population.
The NSAID-MI relationship has been studied before using claims databases with a focus
on older cohorts. However, NSAIDs are increasingly been used among younger cohorts. This
study focuses on a younger cohort (aged 30-64 years) in a population that demonstrates an
increased burden for cardiovascular diseases (Rugg, Bailey, & Browning, 2008). Figure 4.1 shows
the prevalence of MI in Kentucky has been consistently higher than the rest of the US for the
time for which data is available. Additionally, the prevalence of chronic conditions, which are
risk factors for cardiovascular diseases, continue to increase even in younger populations (CDC,
2005-2010). Finally, in most studies the data window has been less than or equal to three years.
Tables 2.1 and 2.2 lists selected studies and their follow-ups. This study has a 12-year data
window period allowing for the possibility of longer follow-ups (maximum 12 years) for the
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patients and the observation of delayed risk. The data for this study consists of administrative
and prescription claims files for Kentucky (KY) Medicaid recipients from January 1st 2000 to
December 31st 2012. This study only considers patients in the time that they were continuously
enrolled in the Kentucky Medicaid program.
Finally, low socio-economic status has been established as a risk factor for
cardiovascular diseases (Rugg et al., 2008). This data comprises low-income patients from a
government-assisted insurance program.
This study aims to investigate the association between NSAIDs and MI using a younger
cohort with recent information from a large claims database: Kentucky Medicaid records. The
three specific aims of this study are:
1. To understand the characteristics of the Kentucky Medicaid population in terms of
NSAID use.
2. To evaluate the NSAID-MI association with a 12-year follow-up in a young
population that demonstrates an increased burden for cardiovascular diseases.
3. To evaluate the MI risk of meloxicam, celecoxib and naproxen compared to no
exposure.
These three aims will make three papers that are the main body of this dissertation. The
Kentucky Medicaid data is comprised of demographic, prescription and medical files for its
recipients.
Chapter two is a literature review of the concepts used in this study. It examines
research on NSAIDs and MI. It looks at the history of the medication, the different studies used
to assess the NSAIDs-MI association and the limitations of these studies. It has a section on
administrative databases. This section outlines their advantages and disadvantages and focuses
on the Kentucky Medicaid population.
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Chapter three examines the characteristics of the Kentucky Medicaid population in
terms of NSAIDs use. It consists of two sections. The first section examines the Medicaid
population to understand the demographic characteristics of the population. The second section
examines NSAIDs use in the population. It evaluates how people use the medication and the
drugs commonly used. This is an important evaluation because different providers used by the
Medicaid program have varied preferred lists of medications. The demographics and NSAID use
of the population were compared to national samples where applicable.
Chapter four examines the NSAID-MI relationship with a 12-year follow-up in a younger
population (30-64 years) heavily burdened with cardiovascular diseases using a nested casecontrol design, where exposure was defined based on the NSAIDs prescribed to the patient,
taking into consideration duration on the medication and whether the prescriptions were
continuous or sporadic; the outcome is a hospital diagnosis of MI. The classification of users into
sporadic vs continuous users is important because sporadic use of NSAIDs has been identified as
a possible source of misclassification (Levesque, Brophy, & Zhang, 2005). This study makes use
of both continuous and sporadic users of NSAIDs by taking into consideration patient adherence
behaviors. The data for this study shows that about 50% of NSAID users in Kentucky Medicaid
are continuous users while the rest are sporadic users. The analysis in this chapter accounted for
several factors known to affect the NSAID-MI relationship. Demographic, comorbid conditions
and concomitant medication were the main factors considered. These were compiled from an
exhaustive search of the NSAIDs-MI literature. Cases were matched to four controls using
incidence density sampling. Conditional logistic regression was used to estimate odds ratios and
their associated confidence intervals (CI).
Chapter five evaluates the MI risk of meloxicam, celecoxib and naproxen compared to
no exposure also using a nested case-control analysis. Cases were also matched to four controls
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using incidence density sampling. Conditional logistic regression was used for the analysis of
these comparisons. Risk factors were considered in this analysis and included as covariates in
the model. Associated confidence intervals were reported for all estimates.
Chapter six discusses the findings of previous chapters, gives recommendations and
implications for medical and public health practices in general and discusses the limitations of
the study. This chapter also looked at areas for further research and development in the
ongoing monitoring of the NSAIDs-MI association.
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Chapter Two
Literature Review
NSAIDs and MI
NSAIDs were discovered in the 19th century by German scientists who recovered
salicylate from willow bark (Fuster & Sweeny, 2011). Next, indomethacin, was developed in
1960. Since then, there have been a number of drugs developed and marketed in the US. They
are commonly used for the treatment of acute and chronic pain. They are widely prescribed as
analgesics and anti-inflammatory drugs at lower and higher doses, respectively. They account
for a large volume of prescription and over- the- counter (OTC) medications worldwide (Green,
2001). In the US, they account for an estimated 5% of all prescriptions (Trelle et al., 2011). At
the turn of this century an estimated 70 million prescriptions and 30 billion OTC tablets were
sold in the US annually.
Most NSAIDs are consumed orally, yet a few are taken intravenously or in the form of a
gel. While they are differentiated in terms of potency, they are not easily differentiated in terms
of efficacy. For example, the coxibs are generally stronger than COX-1. However, there has not
been a consensus in showing one NSAID or class to be stronger than others due to the variation
in patient’s reaction to the drug. They are advantageous because they are not addictive and do
not result in sedation or respiratory depression (Green, 2001).
NSAIDs are not without side effects. The most common adverse reactions relate to
irritation, ulcers and bleeding of the upper GI tracts. It is estimated that over 103, 000 patients
are hospitalized and 16,500 die annually in the US as a result of NSAID associated GI events
(Singh et al., 2006). Another side effect is renal disease. Studies have shown that renal function,
especially in the elderly, can be impaired by some NSAIDs (Moodley, 2008).They have the ability
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to also cause fluid retention. They have also been associated with adverse cardiovascular
events.
NSAIDs block the COX enzymes. COX-1 produces prostaglandins responsible for
homeostatic functions like maintenance of the GI mucosa and platelet aggregation. COX-2
produces prostaglandins that mediate pain and inflammation. The prostaglandin production is
attenuated by NSAIDs in varying degrees and is the major cause of beneficial and adverse
reactions to the drug. Inhibition of COX-2 results in a decrease in prostacyclin which is a
vasodilator and moderator of platelet activation (Daniel H Solomon et al., 2004). This decrease
in prostacyclin causes an increased production of thromboxane which is responsible for the
cardiovascular adverse events (Cannon et al., 2006).
Thromboxane is a COX-1 mediated product of arachidonic acid (Bresalier et al., 2005). It
causes irreversible platelet aggregation, vasoconstriction and smooth-muscle proliferation.
Prostacyclin is another by product of the acid which reacts with thromboxane for homeostatic
balance. The inhibition of thromboxane, by prostacyclin, constrains platelet aggregation which
has beneficial effects like the risk reduction of MI or stroke. Hence, the GI beneficial effects of
NSAIDs come from inhibition of the COX-2 enzyme while the adverse GI effects come from
inhibition of the COX-1 enzyme (Al-Saeed, 2011).
However, there are a number of other normal biologic and bodily maintenance
functions associated with the COX enzymes and prostaglandins (Green, 2001). For example,
prostaglandins protect the gastric mucosa from acid damage by maintaining adequate blood
flow. The kidneys also depend on prostaglandins for blood flow.
In 1999, COX-2 inhibitors were approved by the Food and Drug Administration (FDA)
and released in the US as a less toxic alternative to COX-1s. Their attraction was the reduction in
pain and inflammation without the GI toxicity of their counterparts. Celecoxib and rofecoxib
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were the first to gain approval (Graham, 2006). They were heavily promoted and became the
most widely prescribed NSAIDs. The COX-2s began to draw attention after a study about their
basic mechanisms shed light on their toxicity (Catella-Lawson et al., 1999). Although they were
as effective as COX-1s in relieving pain there were cardiovascular safety concerns. Concerns
were discovered in 1999 during the preapproval application for rofecoxib, but these were
dismissed because the FDA focused more on the reduced GI toxicity of the drug (Avorn, 2007).
Different kinds of studies have been employed in the study of the NSAIDs-MI
association. The main study types are case-control and retrospective cohort studies. There has
also been a prospective case-control study, several nested case-control studies and metaanalyses. There were several clinical trials done that helped fuel the need for more randomized
and observational studies in the area.
Clinical Trials
Clinical trials were instrumental in uncovering the NSAIDs-MI association. The VIGOR
Trial compared rofecoxib with naproxen in patients with rheumatoid arthritis and found
rofecoxib was associated with a significant risk of thrombotic cardiovascular events (0.4%
versus 0.1%) (Bombardier et al., 2000). However, it was not confirmed whether this was due to
a protective effect of naproxen, an increased risk from rofecoxib or a combination of both.
Additionally, the relative risks reported for the trial varied depending on the source of the
information. The Bombardier et al study reported a fourfold increased risk while figures from
the FDA files reported a five-fold increased risk (Juni et al., 2004).
The Celecoxib Long-term Arthritis Safety Study (CLASS) study compared celecoxib with
other NSAIDs in patients with osteo and rheumatoid arthritis for GI toxicity (Silverstein et al.,
2000). This was a pooled analysis of several trials including the SUccesive Celecoxib Efficacy and
Safety Study-1 (SUCCESS-1) (Singh et al., 2006). There was no difference in the incidence of
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cardiovascular events, including MIs, between celecoxib and NSAIDs when all patients were
compared- 0.3% vs 0.3%. The same pattern was seen when the comparison was made in
patients who were not taking aspirin. The study was re-analyzed with similar results (White et
al., 2002).
The APC (Adenoma Prevention with Celecoxib) Trial which focused on the prevention of
colorectal adenomas concluded patients exposed to celecoxib were at a significant risk for
cardiovascular events (S. D. Solomon et al., 2005). This risk had a dose response relationship
and led to the premature end of the trial after 3 years of follow-up. This study found an increase
in death from cardiovascular diseases with use of celecoxib when compared to placebo (HR
=3.4[1.4, 7.8]).
The APPROVe Trial (Atheromatous Polyp Prevention on Vioxx Trial) compared rofecoxib
with placebo in patients with a history of colorectal adenomas and found a significant risk for
cardiovascular events associated with rofecoxib (Bresalier et al., 2005). The trial occurred at 108
centers in 29 countries. This was the first relatively long-term large, multicenter, double-blind
randomized trial comparing a selective COX-2 inhibitor with a placebo. Patients in the rofecoxib
group had an increased incidence of cardiac events of which the majority were MIs (HR=2.8
[1.44-5.45]). The study was prematurely terminated as a result of adverse clinical events. In
September 2004, Merck voluntarily withdrew rofecoxib from the market based on preliminary
results of this trial.
The Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme, a
pooled analysis of data from three trials, compared etoricoxib with diclofenac in patients with
osteoarthritis and rheumatoid arthritis and found similar rates of thrombotic cardiovascular
events for the two drugs (Cannon et al., 2006). The event rates for thrombotic cardiovascular
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events for etoricoxib and diclofenac were 1.24 and 1.30 per 100 patient years respectively. The
hazard ratio for etoricoxib compared with diclofenac was 0.95 (0.81, 1.11).
One of the limitations of clinical trials in the study of the NSAIDs-MI association is they
were focused on older people. The average age of the cohorts in the trials was older than 50
years. Secondly, in clinical trials involving chronic conditions the follow-up time is usually short
providing insufficient time to discover meaningful trends. Table 2.1 provides follow-up durations
for selected trials. Clinical trials suffer from this limitation because the longer the trial the more
expensive it becomes. In the trials mentioned above, those with more patients tended to have
shorter follow-ups. Additionally, clinical trials can be expensive to undertake which is also a
reason why they tend to be short. Finally, clinical trials are limited because they are carried out
in very controlled conditions. With the heavy inclusion and exclusion criteria involved, the trial
population may not be generalizable to all patients as they limit eligibility to a small minority of
patients who receive treatment. As a result, the post-market population of the drugs might be
very different from the trial population. Observational studies are usually able to adequately
capture the effects of drugs in the post-market population.
In April 2005, the FDA requested Pfizer to withdraw valdecoxib from the market due
primarily to cardiovascular concerns from trials in patients undergoing coronary-artery bypass
grafting (Nussmeier et al., 2005). They allowed celecoxib to remain on the market and
requested its labeling together with 18 other COX-1s describe the increased risk of
cardiovascular events (Antman et al., 2005). In 2007, the FDA refused approval for etoricoxib
(Avorn, 2007). Celecoxib continues to be widely used despite studies showing an increased risk
of MI associated with use of the drug (Kearney et al 2006).
It was generally believed the COX-2 inhibitors were the ones with an increased risk of
cardiovascular events. However, results from observational studies suggested some of the COX-
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1s also increased risk when compared with other NSAIDs and no NSAID use (Garcia Rodriguez &
Gonzalez-Perez, 2005; Hernandez-Diaz, Varas-Lorenzo, & Garcia Rodriguez, 2006; McGettigan &
Henry, 2006).
Following the VIGOR trial, there has been accumulating evidence from several
observational studies and meta-analysis that COX-1s are associated with increased
cardiovascular risk. However, none of these results are definite and some contradict each other
leading to conflicting results. Some studies have found an increased risk with NSAIDs use (Chan
et al., 2006; Hippisley-Cox & Coupland, 2005; Johnsen et al., 2005; Mamdani et al., 2004), yet
others have found no effect (Garcia Rodriguez et al., 2004; Ray, Stein, Hall, Daugherty, & Griffin,
2002; Schlienger, Jick, & Meier, 2002). And some have even found a protective effect (Juni et al.,
2004; S. E. Kimmel et al., 2004; D. H. Solomon, Glynn, Levin, & Avorn, 2002; Watson, Rhodes,
Cai, & Guess, 2002). However, most of these studies differed in the length of use and dosage of
NSAIDs. Additionally, the endpoints for the studies differed. Some studies looked at acute MI,
some fatal MIs, some non-fatal and some looked at combinations of cardiovascular events. As a
result of the discrepancies in observational studies and clinical trials, low event rates and the
need for more studies, several researchers have undertaken meta-analysis over the years
(Garcia Rodriguez, Gonzalez-Perez, Bueno, & Hwa, 2011; McGettigan & Henry, 2011).
Observational Studies
The first epidemiologic study evaluating the NSAIDs-MI risk followed a large cohort of
164,769 women aged 50-74 years free of a history of coronary heart disease from the General
Practice Research Database (Garcia Rodriguez, Varas, & Patrono, 2000). This study found chronic
use of NSAIDs was not associated with a protective effect of MI (RR=1.32 [0.97-1.81]).
A retrospective cohort study using data from the Tennessee Medicaid program matched
a cohort of new non-aspirin NSAID users between the ages of 50 and 84 years on age, gender
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and start of NSAID use with non-users (Ray, Stein, Hall, et al., 2002). The endpoint was serious
coronary heart disease defined as MI or death from coronary heart disease. The study found an
absence of a significant protective effect of naproxen (RR=0.95[0.82-1.09]) and other NSAIDs on
risk of coronary heart disease in a high risk population. The same researchers published a study
on COX-2 NSAIDs and risk of serious coronary heart disease reporting users of high dose
rofecoxib were 1.7[0.98-2.95] times more likely to have coronary heart disease compared to
non-users (Ray, Stein, Daugherty, et al., 2002). This risk was increased in new users 1.93[1.093.42]. However, there was no increased risk of coronary heart disease in users of low dose
rofecoxib and other NSAIDs.
A cohort study of elderly patients older than 66 years who were dispensed selective
NSAIDs, naproxen and other NSAIDs compared the rates of MI across groups (Mamdani et al.,
2003).The cohort was identified from administrative health care data from Ontario, Canada.
This study found no significant difference in short-term MI risk for new users of celecoxib
(RR=0.9[0.7-1.2]), rofecoxib (RR=1.0[0.8-1.4]), naproxen (RR=1.0[0.6-1.7]) and other NSAIDs
(RR=1.2[0.9-1.4]).
A prospective cohort study conducted with 70,971 women aged 44 to 69 years
examined the influence of NSAIDs and acetaminophen on the risk of major cardiovascular
events (nonfatal MI, fatal coronary heart disease, nonfatal and fatal stroke) (Chan et al., 2006).
These women were free of cardiovascular disease or cancer and provided up to 12 years of
follow-up. The study concluded use of NSAIDs and acetaminophen at high doses and frequency
was associated with a significant increased risk of cardiovascular disease (RR =1.44[1.27-1.65]).
Specifically, non-fatal MIs had the highest incidence of the four cardiovascular diseases studied
(814 out of 2041) and a consistently elevated risk was found for non-fatal MI for women who
frequently used NSAIDs (1.55[RR=1.26-1.90]).
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A case-control study investigating the NSAIDs-MI association and the possible
interaction with aspirin concluded they are associated with reduced odds in the absence of
aspirin (odds ratio (OR) = 0.53 [0.42-0.67]) and there was no additional protection of aspirin
(OR=0.83[0.58-1.17]) (S. E. Kimmel et al., 2004). This study accounted for OTC use of both drugs.
Cases between the ages of 40 and 75 years with a first non-fatal MI were identified from 36
hospitals in a five-county region surrounding Philadelphia, PA. Approximately four controls were
selected for each case. The researchers conducted another study to assess the effect of COX-2
inhibitors on the risk of non-fatal MI (Stephen E Kimmel et al., 2005). They concluded celecoxib
and rofecoxib were associated with different odds of MI. The adjusted odds ratio of MI for
rofecoxib compared to no NSAID use was 1.16[0.70-1.93] compared to 0.43[0.23-0.79] for
celecoxib.
A matched case-control study evaluated the risk of MI among users of celecoxib,
rofecoxib and NSAIDs in Medicare beneficiaries with a comprehensive drug benefit (Daniel H
Solomon et al., 2004). It consisted of 54,475 patients older than 65 years who received
medication from two state-sponsored pharmaceutical benefits program. It found current use of
rofecoxib was associated with an elevated risk of MI compared with celecoxib (OR=1.24[1.051.46]) and no NSAID use (OR=1.14[1.00-1.31]).
A nested case-control study evaluating the risk of coronary heart disease from selective
and non-selective NSAIDs using data from Kaiser Permanente was conducted in patients 18 to
84 years (Graham et al., 2005). 8143 cases of serious coronary heart disease (MI and sudden
cardiac arrest) were risk set matched with four controls for age, sex and health plan region. This
study found an increased risk of coronary heart disease with rofecoxib (RR=1.59 [1.10-2.32])
when compared with celecoxib. Additionally, the study did not find a protective effect for
naproxen (RR=1.14 [1.00-1.30]) when compared with remote NSAID use.
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A time-matched, nested case-control study used a computerized health insurance and
vital statistics database in, Canada (Lévesque, Brophy, & Zhang, 2005). The cohort consisted of
113,927 elderly persons, aged 66 years and above, without previous MI and newly treated with
NSAIDs. They found a significant increased risk of MI in current users of rofecoxib. This risk was
dose dependent (RR=1.24[1.05-1.46]). There was no evidence of an increased risk with other
NSAIDs.
Meta Analyses
A meta-analysis of 18 randomized control trials (RCTs) and 11 observational studies
compared health effects of rofecoxib with other NSAIDs or placebo (Juni et al., 2004). The study
concluded rofecoxib should have been withdrawn from the market earlier. They found a
substantial increased risk of MI for rofecoxib as early as 2000 which was present for short and
long term use (2.30 [1.22-4.33]). They also found a possible protective effect for naproxen was
not large enough to explain the findings of the VIGOR trial. The relative risk of naproxen was
0.86 (0.75-0.99).
A systematic review of 23 controlled observational studies found cardiovascular risk was
increased with use of rofecoxib, diclofenac and indomethacin (McGettigan & Henry, 2006). The
risk for rofecoxib was present at high and low doses. The relative risks were 2.19 (1.64-2.91) and
1.33 (1.00-1.79) respectively. Additionally, they found naproxen did not have a protective effect
as posited by previous studies with relative risk 0.97 (0.87-1.07). They updated their review
with recently published data and confirmed the findings of the former study (McGettigan &
Henry, 2011). The new analysis also included information on some less studied drugs like
etodolac, meloxicam, indomethacin and piroxicam. In pairwise comparisons of meloxicam with
naproxen the pooled relative risk was 1.11(1.00, 1.23).
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A review of 16 observational studies found naproxen had a non-significant reduced risk
for MI when compared to non-users of NSAIDs with pooled estimates 0.98 (0.92, 1.05)
(Hernandez-Diaz et al., 2006). Diclofenac and ibuprofen had an increased risk with estimates of
1.44 (1.32, 1.56) and 1.07 (1.02-1.12) respectively. They also found an increased risk for
rofecoxib especially at higher doses compared to lower doses. However, they did not find a
significantly increased risk for celecoxib even at higher doses with relative risk 0.96 (0.90, 1.02).
Kearney et al (2006) conducted a meta-analysis of 138 randomized trials that included a
comparison of a COX-2 and a placebo or a COX-1. For inclusion in the analysis, the trial had to be
at least four weeks in duration and contain information on serious vascular events defined as
MI, stroke or vascular death. They found users of COX-2 inhibitors had a 42% increased
incidence of serious vascular events in placebo comparisons with rate ratio 1.42 (1.13, 1.78).
This was due mainly to a two-fold increased risk of MI. Incidence of serious vascular events was
not significantly different between COX-2 inhibitors and COX-1s. They concluded COX-2
inhibitors together with ibuprofen and diclofenac at high doses were associated with an
increased risk of vascular events.
Garcia-Rodriguez et al (2011) concluded both NSAIDs treatment increased risk of nonfatal MI. However, they had insufficient data to assess the risk of fatal and non-fatal MIs for
individual NSAIDs and whether there is a difference between other NSAIDs and the coxibs.
Summary
The literature as to whether NSAIDs affect MI risk is still unclear at least for some of the
medications (Hernandez-Diaz et al., 2006). Tables 2.1 and 2.2 list clinical trials and observational
studies that have evaluated the NSAID-MI relationship with their findings. Few sufficiently
powered RCTs had as their primary objective the assessment of the cardiovascular effects of
NSAIDs (Juni et al., 2004). The NSAIDs-MI association remains an important question, especially
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given their increased use. A slight increase in risk may have considerable public health
implications. Additionally, the removal of certain drugs means the increased use of other drugs
still on the market. Uncertainty remains about the cardiovascular risk of the other NSAIDS
(Roumie et al., 2009). A recent study from Taiwan found increased MI risk associated with
current use of some NSAIDs (Shau et al., 2012).
Several studies used administrative databases to assess the NSAIDs-MI association
(Graham et al., 2005; S. E. Kimmel et al., 2004; McGettigan & Henry, 2011). These studies
employed different methods to account for the limitations of their use. One of the major
limitations is the lack of information on important confounders such as smoking, body mass
index (BMI), family history of MI and use of OTC drugs. Graham et al (2005) conducted a
telephone survey and found the missing factors were not differentially distributed by NSAID use.
In a nation-wide in-home survey of Medicare beneficiaries using different NSAIDs, they did not
differ by BMI, smoking behavior, aspirin use, or educational level (Daniel H Solomon et al.,
2004). Kimmel et al (2004) found no difference in smoking when comparing NSAID users to nonusers. Therefore, in studies of populations which did not measure these potential confounders,
it is likely they were non-differentially distributed across groups. Their impact on the study is
likely to be minimal and biased the study results towards the null or no-effect hypothesis (Ray,
Stein, Hall, et al., 2002; Daniel H Solomon et al., 2004).
Several studies have called for further studies to identify which NSAIDs minimize overall
burden of adverse cardiovascular risk (Kearney et al., 2006; Stephen E Kimmel et al., 2005;
Moodley, 2008). Additionally, due to the conflicting results obtained over the years, further
studies are warranted for a better understanding of the NSAIDs-MI association (Vanasse, de
Brum-Fernandes, & Courteau, 2009).
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Table 2.1. Summary of Clinical Trials

Trial
VIGOR
CLASS
APC
APPROVe
TARGET
MEDAL

Date
2000
2000
2005
2005
2004
2006

Author
Drugs
Follow up
Sample Size Results*
Bombardier et al
Rofecoxib, Naproxen
13 months
8076
Yes
Silverstein et al Celecoxib, Ibuprofen, Diclofenac
17 months
8059
No
Solomon et al
Celecoxib, Placebo
3.1 years
2035
Yes
Bresalier et al
Rofecoxib, Placebo
3 years
2586
Yes
Farkouh et al Lumiracoxib, Naproxen, Ibuprofen
1 year
18325
No
Cannon et al
Etoricoxib, Diclofenac
18 months (average)
34701
No

*Yes implies an increased risk and no implies neutral or reduced risk for MI or related events

Table 2.2. Summary of Observational Studies

Author
Ray et al 2002
Mamdani et al 2003
Chan et al 2006
Kimmel et al 2004
Solomon et al 2004
Graham et al 2005
Levesque et al 2005

Drugs
Rofecoxib,Celecoxib, Naproxen
Ibuprofen
Rofecoxib, Celecoxib, Naproxen
Non-naproxen non-selective
NSAIDs
Rofecxib, Celecoxib. Naproxen
Ibuprofen,
Ibuprofen, Naproxen
Rofecoxib, Celecoxib, Ibuprofen
Naproxen, Other NSAIDs
Rofecoxib, Celecoxib, Naproxen
Rofecoxib, Celecoxib, Naproxen,
Meloxicam, Other NSAIDs

Rofecoxib, Celecoxib, Ibuprofen
Hippisley-Cox et al 2005 Diclofenac, Meloxicam, Etoricoxib
Etodolac, Valdecoxib
Vanasse et al 2009

Rofecoxib, Celecoxib,
Other NSAIDs

Study type

Exposure Period

Outcomes

Sample Size Results*

RCS

1992-1994

MI and CHD

362882

NO

RCS

1998-2001

MI

166964

NO

PCS

1990-2002

MI, CHD AND STROKE

70971

YES

CCS

1998-2001

MI

5208

NO

CCS

1998-2000

MI

54475

YES

NCC

1999-2001

MI AND CARDIAC DEATH

39639

YES

NCC

1999-2002

MI

113927

YES

NCC

2000-2004

MI

95567

YES

NCC

1999-2002

MI

416283

YES

*Yes implies an increased risk and no implies neutral or reduced risk for MI or related events
NCC=nested case-control study, RCS=retrospective cohort study, PCS= prospective cohort study
CCS=case-control study, CHD=coronary heart disease
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Limitations
There are several limitations in the study of the NSAID-MI association. These include but
are not limited to stringent definition of NSAID use, short duration of follow-up and difficulty in
using clinical trials in evaluating this relationship. First, several studies have used conservative
rules to define drug use. In clinical trials, medication compliance rules are strictly followed.
Patients are routinely monitored to make sure they take the drugs as prescribed (Bombardier et
al., 2000; Silverstein et al., 2000). Failure to do so will mean exclusion from the study. Some
observational studies have also followed this trend. For example, Mamdani et al (2003) allowed
a 20% grace period on the previous days prescription to determine continuous use. In general
most prescription lengths are 30 days which would mean that patients who fill in their
prescription within 6 days from end of the previous prescription will be considered continuous
users. This was considered very conservative given that patients miss several days of their
prescriptions and might have extra pills from previous prescriptions which may delay their
refilling of prescriptions. Additionally, the half-lives of these drugs is on average about 18hrs
(almost a day) and if one has been on prescriptions for a while it will take more than 20% of the
previous days prescriptions for the drug to wash out of the body system (Davies & Skjodt, 2000).
Furthermore, intermittent use of NSAIDs has been identified as a possible source of
misclassification in NSAID studies (Levesque et al., 2005).
Secondly there was short duration of follow-up in both clinical trials and observational
studies that have investigated this relationship. A review of the literature showed that the range
of follow-up for clinical trials was from 13 months to 3 years (Bombardier et al., 2000; Bresalier
et al., 2005; Cannon et al., 2006). A review of observational studies showed the same pattern
with the average follow-up being about 3 years (Chan et al., 2006; Graham et al., 2005;
Levesque et al., 2005). It is not known how long the increased cardiovascular risk associated
with NSAIDs persists and to our knowledge no studies have been done to assess this (Ross,
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Madigan, Konstam, Egilman, & Krumholz, 2010). However, longer follow-ups might be able to
access prolonged risk should it exist. This study has a longer period of follow-up (12 years) than
most other studies with the possibility of determining long term effects that may persist even
after discontinuation of the drug. This is very valuable for an observational study considering the
time and money involved in carrying out a clinical trial for the same period of time.
Thirdly, several studies have called for randomized trials to ascertain and understand
this relationship (Kearney et al., 2006; Stephen E Kimmel et al., 2005; Moodley, 2008; Roumie et
al., 2009). However, this is difficult due to ethical considerations in withholding treatment from
patients and randomizing patients to treatment groups. Since NSAIDs are mostly used in the
treatment of chronic conditions, this becomes a serious problem. In the absence of clinical trials
whose primary aim is the investigation of the NSAID-MI relationship more observational studies
are needed to ascertain the relationship and provide timely assessments of drug safety. In this
regard, observational studies of this type present value in post marketing surveillance of drugs.
Finally, not much is known about the adverse effects of meloxicam (McGettigan &
Henry, 2011). Because a considerable number of study subjects were prescribed this drug, this
study attempts to shed some light on this drug- that is increasing in use. Figure 3.4 shows the
increase in use of meloxicam over the years. Furthermore, this study investigates celecoxib, one
of the original COX-2 inhibitors released in early 2000. It was never withdrawn from the market
and a follow-up of this drug is warranted.
Additionally, there is not the ability to control for many covariates that are associated
with MIs. For an inclusion of many variables into a model the sample size has to also be
adequate. This study has a large population and the ability to attempt to control for many
covariates analytically. And it assesses the influence of comorbidities which few studies have
included in their analysis.
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Secondary data are becoming increasingly popular due to the time and expenses
involved in obtaining primary data and the availability of “big data”. There are several challenges
involved in handling secondary data which pose problems for confounding and its suitable
adjustment in observational studies. Understanding and accounting for these challenges is
warranted. This study describes the characteristics of large claims data and provides experience
and recommendations for their efficient use.
Finally amidst all the confusion none of these studies have studied the class of NSAIDs as
a whole even though the FDA deems all of them as such. Some drugs have been less studied
than others.
Administrative Databases
Administrative databases are electronic records of transactions that occurred between
patients and health care providers (Ferver, Burton, & Jesilow, 2009). They consist of billing
codes that health care providers (e.g. hospitals and pharmacies) submit to public (e.g. Medicaid)
or private (e.g. Humana) third party payers. Though primarily used for billing purposes, they are
increasingly used for research. A PUBMED search for “claims data” showed their citations have
increased exponentially over the years.
There are different types of claims data. They are divided into outpatient, inpatient and
pharmacy claims and enrollment data. The outpatient claims contain information about the
patient, date of the service, provider, and place of service, medical procedure and diagnoses
codes. The inpatient claims includes begin and end dates and discharge diagnoses codes
associated with the hospitalization. The pharmacy claims contain patient information,
prescription dates, national drug code (NDC), day’s supply and quantity of drugs dispensed. The
enrollment data includes enrollment history, gender, year of birth, race, insurance plan type and
geographic region.
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There are several advantages of claims databases. First, they provide a comprehensive
view of the patients-healthcare system interaction. This allows for an assessment of the
different components of care and the associations between them (Motheral & Fairman, 1997).
Secondly, they are flexible in terms of study method options. Due to their retrospective nature,
the ethical issues of randomizations are avoided. They can also be useful in research that
involves use of sensitive information if they are de-identified. They are less expensive (Ferver et
al., 2009). Finally, they provide enough statistical power.
One of the limitations is that they are not generalizable to the population. They are
limited to patients who are insured. In the case of Medicaid, they are limited to insured low
income patients. Claims databases have the possibility of miscoding in the form of under-coding
or over-coding. Over-coding occurs when providers include more diagnoses codes to represent a
patient’s medical condition. Under-coding occurs when providers limit the number of diagnoses
codes because there is no incentive to report certain codes as they will not be reimbursed for
such procedures (Motheral & Fairman, 1997). This can lead to misclassification of outcome.
Thirdly, they lack certain information like OTC medication, smoking, body mass index (Ferver et
al., 2009). This becomes a major limitation with regards to the adequate control of
confounding. However, researchers have come up with proxy measures and secondary analyses
methods to curb this limitation. For example, the lack of information on OTC medication varies
from database to database. The extent to which this is lacking is dependent on the patients’
copayment. For public insurance companies that cover everything this lack of OTC medication
may be minimal. For example, in the Kentucky Medicaid, the copays can be as little as a $1.
Finally, the use of claims data files can be complicated due to large, cumbersome and complex
files (Scerbo, Dickstein, & Wilson, 2001).
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Medicaid
Medicaid is a public, health and long-term care coverage program that is jointly financed
by states and the federal government. It is the largest source of funding for medical and health
related services for low-income people in the US. Federal law requires certain mandatory
eligibility groups. These include qualified parents, children, pregnant women, older adults and
the disabled with low income. Each state establishes and manages their own program and
determines the services that are offered. There are certain mandatory benefits and states can
choose to provide other optional benefits.
Kentucky Medicaid enrolls about 22% of the state population (Kentucky Cabinet for
Health and Family Services, 2014). Enrollment and payments have increased steadily in the past
years. Of those enrolled 92% are under managed care. Services included under the Kentucky
Medicaid agreement include doctor visits, emergency and hospital care, vaccinations,
prescription drugs, vision, hearing, long-term care and preventative care for children. Patients
can receive these services for a small copayment. For drugs the copayments depend on whether
the drug is a generic, preferred brand or non-preferred brand.
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Chapter Three
Characteristics of the Kentucky Medicaid Population in terms of NSAID Use
Introduction
NSAIDs are among the most widely used medications and account for a huge volume of
both prescription and OTC medications worldwide (Green, 2001). In the US, they account for an
estimated 5% of all prescriptions (Trelle et al., 2011). They are most commonly used for the
treatment of acute and chronic pain. At the turn of this century an estimated 70 million
prescriptions and 30 billion OTC tablets were sold in the US annually.
There are generally two types of NSAIDs- selective (COX-2) and non-selective (COX-1)
categorized by their ability to inhibit the COX enzyme (Al-Saeed, 2011). The COX enzyme
produces prostaglandins which are attenuated by NSAIDs in varying degrees and is the major
cause of beneficial and adverse reactions to the drug. They are responsible for a number of
normal biologic and bodily maintenance functions (Green, 2001).
COX-1s were the first ones on the market. In 1999, COX-2s were approved by the FDA
and released in the US. Their attraction was they could reduce pain and inflammation without
the GI toxicity of COX-1s. However, they had a minimal effect on platelet aggregation. Celecoxib
and rofecoxib were the first of the COX-2s to gain approval (Graham, 2006). They were heavily
promoted and became the most widely prescribed NSAIDs. A study about their basic
mechanisms shed light on their toxicity and gave much attention to the medications (CatellaLawson et al., 1999). Although they were as effective as COX-1s in relieving pain, there were side
effects which were investigated in clinical trials and observational studies that succeeded these
findings (Bombardier et al., 2000).
In October 2004, rofecoxib was withdrawn from the market after a trial found it
increased the rate of cardiovascular events in some doses. In April 2005, the FDA requested
Pfizer to withdraw valdecoxib from the market due primarily to cardiovascular concerns from
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trials in patients undergoing coronary-artery bypass grafting (Nussmeier et al., 2005). They
allowed celecoxib to remain on the market and requested its labeling together with 18 other
NSAIDs describe the increased risk of cardiovascular diseases (Antman et al., 2005). In 2007, the
FDA refused approval for etoricoxib (Avorn, 2007). Celecoxib continues to be widely used
despite studies showing an increased risk of MI associated with the drug (Kearney et al 2006).
The controversies surrounding NSAIDs are still unclear (Hernandez-Diaz et al., 2006;
Trelle et al., 2011). However, they are still widely used given the increase in chronic diseases.
The removal of certain drugs meant the increased use of other drugs for which uncertainty
remains (McGettigan & Henry, 2011). For example, in Australia the withdrawal of rofecoxib from
the market led to the increased use of meloxicam. Due to their increasing and widespread use, a
study of the present use of NSAIDs is warranted for an understanding of the pattern of use and
possible repercussions (Barozzi & Tett, 2007).
This study aims to document the characteristics of a younger (30-64 years) Medicaid
population and their use of NSAIDs. The study will look at geographical factors of NSAID use and
trends over the years.
Methods
A retrospective cohort study, was conducted to examine NSAIDs use among Kentucky Medicaid
enrollees between the ages of 30 and 64 years who had taken NSAIDS between January 1st 2000
and December 31st 2012.
Data Source
Data for this study represents administrative and prescription claims files of Kentucky
Medicaid enrollees between the above mentioned dates. The enrollees are of low-income socioeconomic status. Enrollment and patient demographic information are included in an
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enrollment file. Prescription files contain dates, drug name, quantity, dose and number of days
supply.
The final data comprises persons aged 30 to 64 years. Patients were eligible if they were
enrolled in Kentucky Medicaid between January 1st 2000 and December 31st 2012, had date of
birth and gender and filled prescriptions during the study. Enrollees were followed until
observance of the first of either end of eligibility, end of medication use, 65th birthday, death or
the end of the follow-up period (December 31, 2012). For this study continuous use of NSAIDs
was considered consecutive prescriptions with a gap of less than 30 days between them. This
was done because patients usually miss a couple of days when on medications and the half-lives
of the drugs considered was on average about 18 hours (Davies & Skjodt, 2000). Additionally, a
distribution of medication gaps showed that this was a reasonable decision. Figure 3.1 shows
the study design.

End of follow-up, first of
1. End of eligibility
2. End of medication
th
3. 65 Birthday
4. Death
5. End of study

Index date (t0): First
Prescription of NSAID

Follow-up
period

Figure 3.1 Study Design

Medicare Part D is a federal program that subsidizes the cost of prescription drugs for
beneficiaries in the US (Medicare, 2014). It was enacted as part of the Medicare Modernization
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Act in 2003 and went into effect in 2006. As a result, there are people in the Medicaid program
who are dually eligible for both Medicare Part D and Medicaid after the age of 65. Such dually
eligible individuals are transferred to Medicare Part D for their prescription drug coverage. As a
result, subjects were removed from the study cohort when they turned 65 years due to lack of
information on prescriptions.
Churning is a phenomenon that is present in large claims databases especially Medicaid
(Saunders & Alexander, 2009). This is the tendency for subjects to move in and out of the
system as indicated by different effective dates. Primarily, in the Kentucky Medicaid program,
any time a subject’s enrollment is touched it ends the segment and starts a new one. Some
reasons for this include but are not limited to changes in eligibility and other demographic
factors. For example, if a subject is continuously enrolled for a period and they make a name or
address change, then that period is divided into two segments. A segment is defined by specific
effective and end dates which mark the beginning and end respectively. For this study,
consecutive segments with no gaps were considered as one segment. The Medicaid database
also included overlapping segments. For example, a patient might have a segment with
effective and end dates of 1-1-2002 and 4-17-2003 respectively. Then they might have another
segment with effective and end dates of 2-1-2002 and 9-30-2002. Since the second segment is
completely contained in the first segment then the first was taken and the second discarded. In
the event of partial overlap of segments, the earliest effective date was chosen as the effective
date for the combined segment and the latest end date was chosen as the end date of the
combined segment.
For this study, patients who were enrolled in the program prior to January 1st 2000 had
their beginning dates shifted to that date and patients who were in the program past December
31st 2012 had their follow-up end dates changed to that date.
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Due to segment changes, some subjects were missing demographic information or had
information change between segments. If the missing information in one segment was found in
another segment then the information was updated. For example, a subject with five segments
might have race available for two of the five segments. Their race was updated in the three
segments with what was found in the two segments. Additionally, there were patients who had
different demographic information in their segments. To overcome this situation, frequencies
were taken for the possible options and the option with the highest frequency was used. For
example, if a patient was male for four out of six segments then the patient was considered a
male. This procedure was used for gender, race and county of residence. The rational for doing
this for county was that the county where the subject spent the most time might have an effect
on access to health care and economic opportunities.
Kentucky consists of 120 counties which were divided into the Appalachian, Central and
Delta (Western) regions. The Appalachian part of the state was mostly the eastern half while the
central was mostly the metropolitan areas of Louisville, Lexington and Northern Kentucky
together with their surrounding areas. The delta region was the western part of the state. The
map in figure 3.2 shows the division of the state into the three regions (Bostic, 2007).
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Figure 3.2 Map of Kentucky by Region
Outcome
The primary outcome for this study was the type of NSAID as determined by the first
NSAID prescription of the patient. Subjects were categorized into one of two groups COX-2 or
COX-1. For classification purposes, the first exposure carried forward to the rest of the study.
Subjects who had taken rofecoxib, celecoxib, valdecoxib or etodolac were classified as COX-2
users and the rest were classified as COX-1 users. All NSAIDs were identified by their national
drug codes (NDC) and classified into one of the two types described above. NSAIDs and their
different brand names were identified using MULTUM which provides trusted drug information
(Multum, 2013). Table 3.1 lists the different medications and the classes they fall into.
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Table 3.1 List of Medications and their Drug Class

Drug
Celecoxib
Etodolac
Rofecoxib
Valdecoxib
Diclofenac
Diflunisal
Fenoprofen Calcium
Flurbiprofen Sodium
Ibuprofen
Indomethacin
Ketoprofen
Ketorolac Tromethamine
Meclofenamate Sodium
Meloxicam
Naproxen
Piroxicam

Class
Cox-2
Cox-2
Cox-2
Cox-2
Cox-1
Cox-1
Cox-1
Cox-1
Cox-1
Cox-1
Cox-1
Cox-1
Cox-1
Cox-1
Cox-1
Cox-1

Statistical Analysis
SAS 9.3 was used for both data management and statistical analysis. Frequencies and
percentages are presented for the covariates by outcome. Rates of new NSAID use, pattern of
use, trends in use and duration of use are also presented.
The Institutional Review Boards of the University of Kentucky (IRB Number 12-0999P2H) and the State of Kentucky Cabinet for Health and Family Services (CHFS-IRB-DMS-FY13-15)
approved this study.
Results
As shown in Figure 3.3, there were 325,281 individuals 18 or older who had ever
received an NSAID prescription between January 1st 2000 and December 31st 2012. Individuals
were excluded from the study for several reasons. There were 53,692 subjects excluded because
of age restrictions, one because they were missing important demographic covariates and
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31,281 because they were not talking the NSAIDs of interest. The final study population was
240,307 individuals with 958,042 person-years of NSAID exposure. Of these 136,938 (57%) were
new users defined as having at least 6-months of non NSAID use before initiation of an NSAID.
The distribution of demographic variables by outcome is presented in Table 3.2. In both
groups the majority of the population were female (66.5% vs. 68%). There was a differential
proportion in the use of the types of NSAIDs by blacks compared to whites and others. For
blacks the proportion of people using COX-2s was less than that of those using COX-1s (4.3% vs
10.1%). Additionally, the pattern in the distribution of race was different for the two medication
classes. For the COX-1s, most of the users were whites followed by others and then blacks. This
pattern was not seen for COX-2s, where there was a decrease in use from whites to others and
then blacks. Baseline age was also differentially distributed among the two exposure groups.
Though both groups have a decrease in the proportion of users with increase in age, the
proportion distribution of 30-40 year olds was different in the two groups. This was the only age
group where the proportion of COX-1 users was greater than COX-2 users (30.0% vs. 50.9%).
Region was also differentially distributed in both groups with the highest proportion of users
from the Appalachian region, followed by the Central and Delta regions respectively. This
pattern was the same for subjects on both COX-1 and COX-2. Continuous use of medication was
similar between the groups with 55.7% of continuous users among COX-2 users and 58.3%
among COX-1 users.
There were 68,687(28.6%) subjects of the final cohort who were exposed to the two
types of NSAIDs during the study. Of these 33,956 (49.44%) started on a COX-2 before switching
to a COX-1 and the rest did the reverse. The median time to switch was the same for the two
distributions (30 days). However, the range was different with those switching from a COX-1 to a
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COX-2 having a longer range. The ranges were 10 to 3596 days for switching from COX 1-2
versus 30 to 3346 days for switching from COX 2-1.

KY Medicaid enrollees aged 18 and older who
have taken an NSAIDS between 2000 and 2012
N=325,281
Exclusion Criteria
 Age restriction (53,692)
 Missing covariate(1)
 Not taking NSAIDs of interest (31,281)
N=84,974
KY Medicaid enrollees aged 30 to 64 who have taken
NSAIDS of interest between 2000 and 2012
N=240,307

COX-1 Users
N=198,148

COX-2 Users
N=42,159

New COX-1 Users
N=117,552

New COX-2 Users
N=19,386

Figure 3.3 Patient identification and cohort entry

Figure 3.4 shows the trends in the number of NSAID prescriptions in the Kentucky
Medicaid population for selected NSAIDs from 2000 to 2012. The graph shows the popularity of
the coxibs (celecoxib and rofecoxib) as they were introduced into the market in 2000. Both
celecoxib and rofecoxib were highly prescribed at the time with about a hundred thousand
prescriptions each. However, this popularity declined over the years, post 2002, to below
twenty thousand prescriptions. This decline gave rise to an increase in prescription of other
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drugs namely ibuprofen, naproxen and most recently meloxicam. Diclofenac saw a short lived
increase but has remained mostly constant in this population.

Table 3.2 Characteristics of the population by Outcome

COX2
(N = 47810)

COX1
(N = 192497)

Gender
Female

31795 (66.5%) 130937 (68.0%)

Race
White

40663 (85.1%) 158000 (82.1%)

Black

2038 (4.3%)

19346 (10.1%)

Other

5109 (10.7%)

15151 (7.9%)

30-<40

14346 (30.0%)

97998 (50.9%)

40-<50

14245 (29.8%)

50058 (26.0%)

50-<60

13509 (28.3%)

34303 (17.8%)

60-<65

5710 (11.9%)

10138 (5.3%)

Appalachian

30888 (64.6%)

91629 (47.6%)

Central

12157 (25.4%)

83261 (43.3%)

4764 (10.0%)

17600 (9.1%)

Baseline Age

Region

Delta/Western
Cont. Users
Yes

26647 (55.7%) 112167 (58.3%)

1. All percentages are column percentages
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Figure 3.4. Trends in NSAID use 2000-2012

The decrease in popularity of the coxibs has meant the increase in popularity of other
NSAIDs. Naproxen and diclofenac saw an associated increase in popularity with the former
becoming the second most commonly prescribed NSAID in the population post 2003. Of
interesting note is the increased use of meloxicam in this population. This drug, which has been
less studied compared to other NSAIDs (McGettigan & Henry, 2006), has grown in popularity to
overcome the coxibs and diclofenac and become more prescribed than naproxen.
In this population there is also an emerging gradual increase in new users of NSAIDs
following a steep decline in the early 2000s. The line in Figure 3.5 shows the trend in the rates of
new NSAID use in the Kentucky Medicaid population from 2000 to 2012, while the bars show
the population of NSAID users for the corresponding years. Even though the prevalent
population has been fairly constant over the years, there is a slight emerging increase in new
use of NSAIDs in this population from 4.9% in 2007 to 6.3% in 2012.
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Figure 3.5 Rate of New NSAID use in the KY Medicaid population 2000-2012

Discussion
The controversial nature of NSAIDs exposure is still discussed in the scientific
community (Gever, 2014). Several studies have had as their aim the investigation of these and
have had conflicting results. As a therapeutic class they share the side effects of gastrointestinal
ulceration, hypersensitivity reactions, inhibition of uterine motility and prostaglandin-mediated
renal function (Antman et al., 2005). Additionally, some of these drugs have been associated
with an increased risk for MI (S. E. Kimmel et al., 2004). Some studies have highlighted the need
for more studies to investigate this relationship. Given the seriousness of some of the side
effects and their effect on the public health, an understanding of NSAID use is warranted.
Specifically, continuous monitoring of NSAIDs use is warranted to curb any potential adverse
effects that they might have.
This study finds that new use of NSAIDs is gradually increasing in the Kentucky Medicaid
population after a decline due to bad publicity. In 2007 new use had dipped to 4.9% but by 2012
new use had increased to 6.3%. There is a high proportion of younger people who are using the
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drugs and they account for this gradual increase in use. From table 3.2, the 30-40 year olds
make up the highest percentage of users in both the COX-1 and COX-2 groups. In this cohort, the
30-40 year olds and the 40-50 year olds were the majority of the incident population of NSAID
users. In 2000, the 30-40 year olds accounted for about 30% of the incidence use population and
by 2012 they accounted for about 60% of the incidence population. Even the enrollees who are
less than 50 years of age are helping to propagate the incidence and prevalence of use in the
population.
This study does not have a wash out period and assumes that an incident prescription of
NSAID in the Medicaid program is an incident use of NSAID. This may not be the case as we do
not have information on OTC medications.
The use of NSAIDs especially in young populations should be closely monitored to track
the possible occurrence of any harmful side effects which might have public health implications
if left unattended.
Using the National Health and Nutrition Examination Survey (NHANES) data, the
prevalence of NSAIDs use for the 30 to 64 year age range used in this study was estimated at
4.4% for the study period. A significant proportion of the population uses these drugs and they
account for a huge volume of prescription medications nationally. As such any adverse side
effects caused by them will have considerable public health implications.
This population compares to the national sample in the NHANES data in several ways. In
both populations women use the medication more than men. More people also use more COX-1
NSAIDS compared to COX-2. About one-third of the NHANES population was on COX-2s
compared to one-fifth of the Kentucky Medicaid population. One precaution in these
comparisons is that the NHANES data mostly measure prevalence of medication use while the
Kentucky Medicaid data measures both incidence and prevalence. This will explain the higher
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proportion of people in the older age groups in the NHANES data compared to the higher
proportion in the younger age groups in the Kentucky Medicaid population.
While race and region may not directly influence access to NSAIDs they might serve as a
proxy for underlying socio-economic factors that serve as an indicator of access. The
Appalachian region of the state leads the rest of the state in use of both COX-1s and COX-2s but
more so the COX-2s. This might be indicative of the prevalence of chronic conditions in that part
of the state compared to the others. It is generally believed this section of the state is
responsible for the low ranks in national health indices as it has a high prevalence of diseases.
This will make geographical location important as a predictor for NSAID drug use in the Kentucky
Medicaid population. Additionally, race was also differentially distributed especially for blacks
which might also be indicative of socio-economic factors.
Based on the literature, the trends in NSAID use for this population mirrors that of the
general US population. Of all the NSAIDs studied the most commonly used medication presently
is ibuprofen. It has consistently achieved one of the highest numbers of prescriptions over the
study period (Figure 3.4). This is understandable as ibuprofen has been around for a long time
and is available under a bunch of generic and trade names. There are over a thousand NDCs
associated with this drug alone. The commonly used Advil falls under this group of drugs.
However, in the early 21st century, COX-2 inhibitors were very popular. They were leading in the
number of prescriptions in this population. This popularity saw a decline after some studies
highlighted their cardiovascular risk. It is hypothesized that this decline was due to the negative
publicity associated with these drugs in terms of their increased risk for MI (Bombardier et al.,
2000; Mukherjee, Nissen, & Topol, 2001). The decline coincides with the publication of research
articles attesting to the increased risk of MI with use of these drugs. This risk was first posited in
2001 with several other studies supporting and disputing said risk over the years. This led to an
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increase in popularity of other NSAIDs. However, studies have also highlighted the
cardiovascular risks of other NSAIDs. This calls for further studies of these drugs and an
understanding of their use in the general population.
Further research into the determinants of the relationship between NSAIDs and their
potential side effects is warranted. Further research will look at factors that potentially affect
these relationships. For example, one of the side effects of NSAIDs is cardiovascular diseases
which have been identified as a leading cause of death worldwide (Alwan 2011). As a result,
anything that would exacerbate this risk is of grave public health concern. Considering that
NSAIDs are widely used in the population even a small increase in adverse side effects will have
considerable public health implications.
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Chapter Four
Understanding MIs in a Younger Medicaid Population
Introduction
NSAIDs are among the most widely used medications and account for a huge volume of
both prescription and OTC medications worldwide (Greene 2001). They are effective for the
management of inflammatory, arthritic and other musculoskeletal conditions (Rahme, Pilote, &
LeLorier, 2002). They are most commonly used for the treatment of acute and chronic pain.
There are generally two types of NSAIDs categorized on their ability to inhibit the COX
enzyme; they are selective (COX-2) and traditional NSAIDs (COX-1)(Al-Saeed, 2011). In 1999,
COX-2s were approved by the FDA and released in the US as a less toxic alternative to COX-1s.
Their attraction was they could reduce pain and inflammation without the upper GI toxicity
identified in other NSAIDs. Celecoxib and rofecoxib were the first to gain approval (Graham
2006). They were heavily promoted and quickly became the most widely prescribed NSAIDs. A
study about their basic mechanisms shed light on their toxicity and gave much attention to the
medications (Catella-Lawson et al 1999). This study highlighted suppression of prostacyclin by
inhibition of the COX-2 enzyme. Although they were as effective as other NSAIDs in relieving
pain, there were cardiovascular concerns such as MI and stroke.
The inhibition of the COX enzyme is the first step in converting arachidonic acid to
prostaglandins, thromboxane and prostacyclin (Catella-Lawson et al., 1999). COX-1 produces
prostaglandins responsible for platelet aggregation and gastric mucosa. COX-2 produces
prostaglandins that mediate pain and inflammation. The inhibition of COX-1 causes bleeding and
that of COX-2 suppresses prostacyclin which reacts with thromboxane for homeostatic balance
(Graham, 2006). This inhibition of prostacyclin causes an increased production of thromboxane
which is responsible for adverse cardiovascular events (Cannon et al., 2006). This mechanism of
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action has been reported to be sufficient to explain the clinical effects of NSAIDs (Patrono &
Baigent, 2014).
Several studies have evaluated the NSAIDs-MI association. The VIGOR Trial reported an
increased risk for MI with use of rofecoxib compared to naproxen (Bombardier et al 2000).
However, it was not confirmed whether this association was due to a protective effect of
naproxen, an increased risk from rofecoxib, or a combination of both. Several other studies and
trials on the NSAIDs-MI association have found conflicting results. The CLASS study compared
celecoxib with other NSAIDs in patients with osteoarthritis and rheumatoid arthritis and found
no difference in cardiovascular events between the groups (Bresalier et al., 2005; Farkouh et al.,
2004; Silverstein et al., 2000; S. D. Solomon et al., 2005).
The APPROVe trial was terminated as a result of adverse clinical events such as MI,
unstable angina, death from cardiac causes, ischemic stroke, ischemic attack, peripheral arterial
thrombosis, peripheral venous thrombosis, and pulmonary embolism. The study found use of
rofecoxib was associated with a significant increased cardiovascular risk when compared to a
placebo in patients with a history of colorectal adenomas (RR=1.92; 1.19-3.11)(Bresalier et al.,
2005). While this study looked at a combination of cardiovascular events, MI was the majority of
such events. In September 2004, Merck voluntarily withdrew rofecoxib from the market based
on preliminary results of this trial. In April 2005, the FDA requested Pfizer to voluntarily
withdraw valdecoxib from the market. This was due primarily to cardiovascular concerns (MI,
cardiac arrest, stroke and pulmonary embolism) produced from trials in patients undergoing
coronary-artery bypass grafting (Nussmeier et al., 2005). The FDA allowed celecoxib to remain
on the market and requested its labeling together with other NSAIDS describe the increased risk
of cardiovascular events (Antman et al., 2005; FDA, 2005). At the time, this was a black-box
warning that was not preceded by investigations for all the medications involved. In 2007, the
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FDA refused approval for etoricoxib because of the possible implications of approving another
COX-2 inhibitor with potentially dangerous cardiac side effects (Avorn, 2007). Celecoxib is still
widely used despite studies showing an increased risk of MI associated with the drug (Kearney
et al., 2006).
Results of some observational studies have suggested that some COX-1s also increased
cardiovascular risk (Garcia Rodriguez & Gonzalez-Perez, 2005; Hernandez-Diaz et al., 2006; Juni
et al., 2004; McGettigan & Henry, 2006). Following the VIGOR trial, there has been accumulating
evidence from several large observational studies and meta-analysis that NSAIDs are associated
with increased cardiovascular risk. However, these results are not conclusive lending to
conflicting results and the need for more studies in this area. While some studies have found an
increased cardiovascular risk with NSAIDs use (Chan et al., 2006; Hippisley-Cox & Coupland,
2005; Johnsen et al., 2005; Mamdani et al., 2004), others have found no effect (Garcia Rodriguez
et al., 2004; Mamdani et al., 2003; Ray, Stein, Daugherty, et al., 2002; Schlienger et al., 2002) .
And some have even found a protective effect with use of some NSAIDs (Juni et al., 2004; S. E.
Kimmel et al., 2004; D. H. Solomon et al., 2002; Watson et al., 2002). As a result of the
discrepancies in the different studies, low event rates and the need for more meaningful
studies, several researchers have undertaken meta-analysis over the years (Garcia Rodriguez et
al., 2011; McGettigan & Henry, 2011). The Garcia Rodriguez et al. study concluded that use of
NSAIDs increased the risk of non-fatal MIs but did not have a substantial effect on fatal ones.
The McGettigan study found that there were different levels of cardiovascular risk among the
most widely used NSAIDs. These studies and their results and methods are listed in tables 2.1
and 2.2.
Whether NSAIDs affect MI risk is still unclear (Gever, 2014; Hernandez-Diaz et al., 2006;
Trelle et al., 2011). The NSAIDs-MI association remains an important question, especially given
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their increased use in an aging population with a high prevalence of chronic diseases.
Additionally, the removal of refocoxib and valdecoxib from the market means the increased use
of other drugs on the market (e.g. meloxicam) for which the cardiovascular risks are not welldefined (McGettigan & Henry, 2011). A recent study from Taiwan found increased MI risk
associated with current use of some NSAIDs including commonly used drugs like ibuprofen and
diclofenac (Shau et al., 2012). Recently, the FDA convened an advisory committee meeting to
assess NSAID safety in an effort to re-evaluate decisions made nearly a decade ago in light of
present evidence (Gever, 2014).
Cardiovascular disease is a leading risk factor for death worldwide (Alwan, 2011). As a
result, continuous monitoring of the NSAID-MI relationship is needed because an agent that
potentially affects such an important risk factor poses considerable public health consequences.
Kentucky is one of the states with the highest prevalence of cardiovascular diseases in the US
(CDC, 2005-2010). According to the Behavioral Risk Factor Surveillance System (BRFSS), from
2005 to 2010 the MI prevalence for Kentucky has been between 5% and 6.5% with the lower
bound of the 95% CI greater than the median percentage for all the other states over the same
period of time. Figure 4.1 shows the prevalence of MI in Kentucky compared to the US from
2005 to 2010.
This study is different in that it investigates the NSAIDs-MI association in a younger
population (30-64 years) heavily burdened with cardiovascular diseases. Also, this study has
more recent data compared to other studies done over a decade ago and it has a longer window
of data (12 years). Secondly this study investigates a possible class effect of NSAIDS which has
been posited by some researchers (Antman et al., 2005). The investigation of a class effect was
done by comparing COX-2s to COX-1s on their risk for MI. Additionally, this study takes into
consideration latent socio-economic factors, by accounting for the geographical region of the
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patients. It also considered switching patterns of medication classes. Finally, this study accounts
for continuous and sporadic use of the medications in the cohort. The intermittent use of
NSAIDs has been identified as a limitation in the study of the NSAIDs-MI association (Levesque
et al., 2005).
While most other studies that have evaluated the NSAID-MI relationship have focused
on age as an important high risk factor for MI, this study highlights socio-economic risk factors
that affect the disease especially in a state like Kentucky where the prevalence of cardiovascular
diseases is very high compared to the rest of the US. As such, the Kentucky population serves as
an important case study for the investigation of this association.

Figure 4.1 Prevalence of MI in KY and US
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1. Percentages are weighted to population characteristics.
2. Data obtained from BRFSS.

Due to the overall health status of the state, younger groups of patients also have an
increased burden for cardiovascular diseases compared to the rest of the country (CDC, 20052010). From 2005-2010, the rates of MI in Kentucky for the different age groups is at or higher
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than the median for the US. This study aims to investigate the NSAIDs-MI relationship in a
younger Medicaid population with the aim of understanding the literature-defined and socioeconomic risk factors in patients exposed to the drug and assessing the possibility of a residual
risk after discontinuation of the drug.
Methods
Study overview
A retrospective cohort study, using the new users design (defined below), was
conducted to examine the NSAIDs-MI relationship among younger (30-64 years) Kentucky
Medicaid enrollees who were prescribed NSAIDs between January 1st 2000 and December 31st
2012 (Ray, 2003). Only patients with an NSAID prescription of interest were selected for entry
into the cohort. Within this cohort we conducted a nested case-control study. The primary
objective of this study was to compare MI events (cases) to non-MI events (controls) between
users of COX-2 and users of COX-1.
Data Source
Data for this study included administrative and prescription claims of Kentucky Medicaid
linked with hospital discharge information and death dates collected between January 1st 2000
and December 31st 2012. Enrollment and patient demographic information were included in an
enrollment file. Prescription files contained dates, drug name, quantity, dose and days of supply.
Hospital and outpatient files included admission and discharge dates for hospitalizations,
outpatient and emergency department visits. Diagnoses associated with hospitalizations and
visits were identified using the International Classification of Diseases, Ninth Revision; Clinical
Modification (ICD-9-CM).
The subjects for this study included persons aged 30 to 64 years at NSAIDs initiation
who were enrolled in Medicaid between 2000 and 2012, had information on demographic
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covariates, had at least one outpatient encounter or filled at least one NSAID prescription and
did not have evidence of serious medical illness in the 6-month baseline period before they
began taking NSAIDs. We restricted patients 65 years and older from entering the cohort
because of the introduction of Medicare Part D in 2006. Serious medical illnesses included HIV
infection (ICD-9-CM 042.x-044.x and 079.53) and organ transplant (ICD-9-CM V42.x). Patients
with serious medical illnesses were excluded because they already have a compromised
immune system (Graham et al., 2005).
Enrollees were followed until observance of study outcome (MI), disenrollment from
the program, their 65th birthday, death or the end of the follow-up period (December 31, 2012),
whichever came first. Only the first occurrence of the study outcome was observed as an
outcome. Figure 4.2 shows the study design.

End of follow up, first of
1. Study outcome
2. Disenrollment in program
3. Death
th
4. 65 Birthday
5. End of study

Index date (t0): First
Prescription of NSAID

6-months Baseline
Period

Follow-up
period

Figure 4.2 Study Design
Exposure classification
The primary exposure was the type of NSAID (COX-2 versus COX-1) used on the index
date, which was the first prescription of an NSAID after the 6-months baseline period defined
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below. The COX-2 and COX-1 users were considered as the exposed and comparison groups
respectively. The COX-2 drugs of interest were rofecoxib, celecoxib, valdecoxib and etodolac.
The COX-1 drugs of interest were diclofenac, diflunisal, fenoprofen, flurbiprofen, ibuprofen,
indomethacin, ketoprofen, ketorolac, meclofenamate, naproxen and piroxicam. These drugs
were identified from the literature as the most commonly used in the study of the NSAIDs-MI
association (McGettigan & Henry 2011). Meloxicam was not considered in this study because it
is usually classified as a COX-1 but not much is known about it. Other studies have hypothesized
that it has a higher COX-2 then COX-1 selectivity (Antman et al., 2005; McGettigan & Henry,
2011; Singh et al., 2006). Figure 3.4 shows the trends in use of meloxicam over the study period.
All NSAIDs of interest were identified by their national drug codes (NDCs) and classified into the
two types using MULTUM (Multum, 2013). The list of drugs studied and their classifications are
presented in table 3.1.
Only new users were included in the analyses. For this study, a new user was defined as
someone who had no prescription of the study drugs in the 6-month baseline period preceding
their first NSAID prescription (index date). A baseline period of 6-months was used as it was
deemed sufficient for any previous use to have left the body and for collecting of baseline
covariates. This period of non-use is synonymous to a wash out period as used in clinical trials.
New users are less susceptible to biases introduced by prevalent users (Ray 2003). These include
but are not limited to the healthy user effect and the effect of prevalent use of drugs on the
covariates measured at study entry.
The primary way in which observational studies differ from clinical trials is that patients
determine whether they take the treatment. As a result, patients will discontinue treatment if
they have adverse reactions to it. This phenomenon of not having an adverse reaction to the
treatment is what has been termed the “healthy user effect”(Ray, 2003). On the other hand,
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prevalent users can cause misclassification of events if they occur early during exposure.
Prevalent users also do not allow for control of certain risk factors that may be affected by the
treatment.
Patients were classified into exposure categories based on their new-user or first NSAID
exposure. Patients were not re-classified for claim changes. Preliminary results show that the
characteristics of the subjects in the two possible switch groups (COX-1-2 and COX-2-1) were
similar by outcome. Furthermore, these results showed the proportion of people who switched
were similar for the two possible switches- from a COX2-1 and vice versa (51.3% vs 48.7%).
Duration of exposure was taken into consideration by summing up the number of days
supply for the patients prescriptions during their time in the study. There were some patients
with very large number of days supply on their prescriptions. As a result, a decision was made
that if a prescription had a number of days supply greater than 90 days then the number of days
supply will be reduced to 90 days. This was done because prescriptions in the Kentucky
Medicaid data usually run from 30 to 90 days.
Finally, patients were classified as continuous versus sporadic drug users. For this study,
continuous use of NSAIDs was defined as consecutive prescriptions with a gap of less than 30
days between prescriptions. Otherwise, they were considered sporadic users. This was done
because patients usually miss a couple of days when on medications and the half-lives of the
drugs under consideration is on average about 18 hours (Davies & Skjodt, 2000). Furthermore, a
distribution of medication gaps showed that this was a reasonable decision.
To compensate for the fact that patients were not re-classified for claim changes,
switching was considered in a separate analysis. Once a patient was classified as a COX-1 or
COX-2 user at study entry, there is the possibility that they could switch from a COX-1 to a COX-2
and vice versa. As a result, switching patterns for the two possible switches were compared to
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those patients who did not switch and stayed on their original classification throughout the
study. Alternatively, exposure was considered as a four category variable; those who took only
COX-1, those who took only COX-2, those who switched from COX-1-2 and those who switched
from COX-2-1.
Outcome
The primary outcome was admission for MI during the study as identified from hospital
discharge diagnosis codes (ICD-9-CM 410.xx) in the primary and secondary diagnoses positions.
This algorithm was validated by a hospital stay of more than 2 days but less than 180 days,
unless the patient died (Petersen, Wright, Normand, & Daley, 1999; Roumie et al., 2009; Daniel
H Solomon et al., 2004). Two days was chosen because shorter stays were unlikely for an
accurate diagnosis of MI. Several studies have validated this algorithm for claims data ICD-9-CM
diagnosis and found greater than 90% for positive predictive value and sensitivity (Graham et al.,
2005; Metcalfe et al., 2013; Roumie et al., 2009; Wahl et al., 2010) . This algorithm has a
specificity greater than 90% (Brouwer et al., 2013). A recent study showed the changes in
sensitivity, specificity, positive and negative predictive values with different algorithms for
ascertaining MI cases from claims data (Brouwer et al., 2013). The algorithm, of a MI admission
identified from the first and second diagnosis positions with a stay of more than 2 days, was
used as it was common in the literature and highlighted as optimal (Brouwer et al., 2013;
Levesque et al., 2005; Roumie et al., 2009). Given the high sensitivity and specificity for this
algorithm, the false negative and positive rates were expected to be relatively low.
For every MI case, we randomly selected four controls from individuals in the study
cohort and matched them for gender and race using incidence density sampling. This is an
efficient approach which produces unbiased estimates of the relative risk (Richardson 2004).
The process involves matching cases to controls who were at risk at the time of case occurrence.
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For example, if a case occurred in 2003, only persons who had entered the cohort at or before
2003 and had not become a case by then will be eligible to be chosen as controls. Controls
matched to a case could later become cases themselves. It solves the problem of controls
providing excess person time to the study than cases.
A SAS macro by Richardson (2004) with some edits was used for the incidence density
sampling. Instead of using age for the macro, date of first NSAID prescription was used as date
of entry into the cohort. Last date in the cohort was the first of either end of segment, 65th
birthday, MI event date, death or end of the study. For matching on race and gender, estimated
probabilities were generated using logistic regression with MI as the outcome and race and
gender as the inputs. The probabilities were then multiplied by a hundred and rounded to the
nearest whole number to form categories which were used for the matching in the macro. This
was done as an alternative method to incorporate matching using propensity scores.
Covariates
Baseline covariates were measured in the 6-months prior to the index date. This was
done to reduce bias that might arise because of varying lengths of covariate assessment
(Solomon et al 2004).
The study covariates included age at initiation, gender, race, state region of residence,
co-morbid conditions, concomitant medication (other non-NSAID medications).
Demographics
Demographic variables were identified from patient enrollment data. Age at initiation
was calculated as the difference between the patient’s year of birth and year of index date.
Gender and race were reported in the Medicaid file. The enrollment file also contained the
patient’s county of residence. This was used to determine Kentucky residence as a categorical
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variable with options: Appalachian, Central and Delta or Western. Figure 3.2 shows the division
of the state into the three regions.
Comorbid Conditions
Comorbid conditions that occurred during the 6-month baseline period were obtained
from Medicaid medical files. The ICD-9-CM codes were used in coding algorithms for the
Elixhauser and Charlson comorbidities (Quan et al., 2005). These algorithms identify
comorbidities from administrative data and they have been validated for such use. Claims data
have a stipulated number of diagnoses and for Medicaid, there are up to ten diagnoses
reported. The following comorbid conditions were assessed based on the literature: angina,
cerebrovascular disease , chronic pulmonary disease (COPD) , congestive heart failure ,
coagulopathy , coronary revascularization , diabetes , hypertension , hypercholesterolemia ,
osteoarthritis , previous MI , and rheumatoid arthritis (Baron et al., 2008; Shau et al., 2012).
Table 4.1 lists the comorbid conditions with their corresponding ICD-9-CM codes.
Concomitant medication
Several methods are used to assess disease severity in the use of claims data. The
use of concomitant medication is one such method and this was identified from the prescription
claims file as those that overlap the index date of NSAID use within a 60 day window centered at
the index date. The main drug classes considered were statins, beta-blockers, anticoagulants,
calcium channel blockers, angiotensin converting enzyme (ACE) inhibitor, angiotensin receptor
blocker (ARB) and diuretics. These were all considered based on the literature (Cannon et al.,
2006; Graham et al., 2005; Daniel H Solomon et al., 2004). Table 4.2 lists the drug classes and
the medications that were considered in those classes. The concomitant medications were all
identified using MULTUM (Multum, 2013).
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Table 4.1 Comorbid conditions and ICD-9-CM Codes
Comorbid Condition
ICD-9-CM Code
Angina
413.0,413.9
Cerebrovascular Disease
430.x – 438.x
Chronic Pulmonary
490.x-496.x
Disease
398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13,
Congestive Heart Failure
404.91, 404.93, 425.4-425.9, 428.x
Coagulopathy
286.x, 287.1, 287.3-287.5
Coronary
414.x
Revascularization
Diabetes
250.xx
Hypertension
401.xx – 405.xx
Hypercholesterolemia
272.0
Osteoarthritis
715.xx
Previous MI
410.x
Rheumatoid Arthritis
446.5, 710.0 –710.4, 714.0—714.2,714.8,725.x

Drug Class
Statins
Beta Blockers

Anticoagulants
Calcium Channel
Blockers
ACE Inhibitors

ARB Medications
Diuretics

Table 4.2 Drug classes and medications
Medications
Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin
Pitavastatin
Kerlone, Zebeta, Tenormin, Toprol-xl, Bystolic, Brevibloc, Sectral, Innopran
XL, Corgard, Betapace, Inderal, Coreg, Labetalol, Timolol, Carteolol, Levatol,
Sorine, Trandate, Pindolol
Clopidogrel, Fondaparinux, Hepharin, Ticlopidine, Warfarin, Enoxaparin,
Dalteparin
Amlodipine, Clevidipine , Isradipine, Felodipine, Nicardipine , Nifedipine,
Nimodipine, Nisoldipine, Verapamil , Diltiazem, Mibefradil A, Fluspirilene
Captopril, Zofenopril, Enalapril , Ramipril , Quinapril , Perindopril , Lisinopril
, Benazepril, Imidapril, Zofenopril, Trandolapril, Fosinopril
(Fositen/Monopril)
Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan,
Candesartan, Eprosartan
Furosemide, Ethacrynic acid, Torsemide, Hydrochlorothiazide,
Acetazolamide, Methazolamide, Chlorothiazide, Indapamide, Metolazone,
Bumetanide, Amiloride, Eplerenone, Spironolactone, Triamterene
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Statistical Analysis
SAS 9.3 was used for both data management and statistical analyses.
This paper examined the NSAID-MI association using patients with a baseline washout
period of 6 months (180 days). The baseline period was used to identify baseline characteristics
and give patients an equal amount of time for these characteristics to be evaluated.
Comparisons were presented of cases and controls in tables using frequencies and
percentages. Tables comparing cases and controls by exposure were also presented to see
differences in case status by exposure for the demographic and risk factors. Conditional logistic
regression was used to evaluate the association between NSAID use and MI taking into
consideration confounders and risk factors not used for matching. Duration of exposure and
continuous use were also considered. COX-2 users were compared to COX-1 users. Age was
assessed as an effect modifier by running the model for the different age categories and
comparing the parameter estimates. The estimated odds ratios approximate the relative risk.
Covariates were determined based on the literature and characterization of the population. The
same model was considered with switching pattern as the exposure. Parameter estimates with
their associated 95% confidence intervals were presented for all comparisons.
The Akaike Information Criteria (AIC) was used to assess model fit and the variance
inflation factor (VIF) was used to evaluate multi-collinearity. The VIFs for all the variables used in
the accepted range that does not indicate multi-collinearity in models (greater than 5 or 10).
Missing data were not an issue as patients missing demographic information were
excluded from the study (Figure 4.3). For comorbid conditions and concomitant medications, a
patient did not have them if the code(s) for those indications were not in their files.
We conducted sensitivity analysis to see the differences between the population that
was used for the study and those excluded due to the new users design. This comparison was
presented using frequencies and percentages.
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The Institutional Review Boards of the University of Kentucky (IRB Number 12-0999P2H) and the Kentucky Cabinet for Health and Family Services (CHFS-IRB-DMS-FY13-15)
approved this study.
Results
Figure 4.3 shows the patient disposition of the study. There were 325,281 subjects 18 or
older who had taken an NSAID in the Kentucky Medicaid program between January 1st 2000 and
December 31st 2012. Of these 232, 645 (71.5%) were between 30 and 64 years at NSAID
initiation, taking an NSAID of interest and had all their demographic covariates. These formed a
cohort of which 184,835 (79.4%) were COX-1 users and 47,810 (20.6%) were COX-2 users.
Patients with a 6-month baseline period without any NSAID prescriptions prior to their first
prescription were considered new users and formed the final cohort. The COX-1 users were
reduced to 106,558 (57.7%) of which 1,084 (1.02%) had an MI. There were 22,718 (47.5%) COX2 users in the final cohort of which 420 (1.84%) had an MI. A total of 129,276 people
contributed 514,525 person-years of observation time to the study. The mean age at NSAID
initiation of the cohort was 42.2 years with a standard deviation of 9.7 years. From this cohort,
there were 1504 cases of MI matched to 6016 controls using incident density sampling matching
on gender and race. Of the 1504 cases, 658 (43.75%) had an MI after last exposure to the drug.
Figure 4.4 shows the trend in NSAIDs initiations by type for the study population. The
popularity of COX-2s is seen by the peak in their prescriptions around 2000 and their
subsequent decline. The prescription of COX-1s has been mostly constant over the years.
Table 4.3 shows the baseline characteristics of the MI cases and controls. It shows the
balance in the variables used for matching. The distribution in age at initiation is different for
cases and controls. Amongst cases, initiation of medication started later compared to controls.
The modal age group for controls was 30-40 years and that of cases was 50-60 years. For
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controls there is a progressive decline in initiation as age increases. However for cases, there is
an increase and then a decrease as age increases.

KY Medicaid enrollees aged 18 and older who
have taken an NSAIDS between 2000 and 2012
N=325,281

Exclusion Criteria
 Age restriction (53,692)
 Missing covariate(1)
 Not taking NSAIDs of interest (38,943)
N=92,636

KY Medicaid enrollees aged 30 to 64 who have taken
NSAIDS of interest between 2000 and 2012
N=232,645

COX-1 Users
N=184,835

COX-2 Users
N=47,810

New COX-1 Users
N=106,558

MI
N=1,084

New COX-2 Users
N=22,718

MI
N=420

NMI
N=105,474

NMI
N=22,298

Figure 4.3 Patient identification and cohort entry

The majority of cases (58.3%) were from Appalachia as opposed to 34.0% and 7.6% from the
Central and Delta regions respectively. The same pattern was repeated for controls. The
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proportion of patients with risk factors among the MI cases was significantly higher than the
controls for all the comorbid conditions and concomitant medications. And in some cases there
is almost a doubling or more of proportions. For example, 6.4% of the MI cases had angina
compared to only 1.8% of the sampled controls.
To investigate if risk factors for MI varied by the type of NSAID, we investigated the
distribution of these factors in MI cases and controls by exposure group. Table 4.4 displays the
results. Among female patients who took a COX-2, there was a higher percentage of MI cases
than controls (58.6% vs 52.9%) but amongst those exposed to COX-1 the reverse was true
(50.3% vs 54.5%). The same pattern, of higher percentages of MI cases than controls amongst
COX-2 users, was repeated for the categories of race with the exception of others. For patients
in the other race category, there was a higher percentage of cases compared to controls among
those exposed to COX-1s (12.2% vs 9.6%) but a higher percentage of controls compared to cases
among those exposed to COX-2s (13.3% vs 12.4%). The distribution of age at initiation was
different with a divide at 50 years. For those less than 50 who were exposed to COX-2, there
was a higher percentage of controls compared to cases. The percentage of control patients in
the 30-<40 and 40-<50 age groups were 31.2% and 34.6% respectively compared to MI case
percentages of 16.4% and 31.4% in the same groups respectively. For those older than 50 years
in the same exposure group, there was a higher percentage of cases compared to controls. For
those exposed to COX-1s, the same pattern repeated itself. Region repeated the same pattern
that was seen in the overall comparison of cases and controls presented in table 4.3, where
there were more MI cases in the Appalachian region followed by the Central and Delta regions,
for the two exposure groups. In both categories, there was a higher proportion of cases than
controls for each of the levels of region with the exception of the Delta region for those exposed
to COX-2s and the Central region for those exposed to COX-1s. In those two scenarios there
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were more controls than cases. For all of the risk factors the percentage of MI cases with the
risk factor was higher than that of controls in both exposure groups.

Figure 4.4. Graph showing the trend in NSAIDs initiation in the KY Medicaid Population
2000-2012
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Table 4.3 Characteristics of the MI cases and matched controls from the base
population
NMI
(N = 5661)

MI
(N = 1504) P-Value

Gender
Female

0.2952
3063 (54.1%)

791 (52.6%)

Race
White

0.1427
4665 (82.4%) 1223 (81.3%)

Black

399 (7.0%)

97 (6.4%)

Other

597 (10.5%)

184 (12.2%)

Age

<.0001

30-<40

2305 (40.7%)

254 (16.9%)

40-<50

1781 (31.5%)

461 (30.7%)

56

Table 4.3, continued
50-<60

1357 (24.0%)

658 (43.8%)

60-<65

218 (3.9%)

131 (8.7%)

Region

0.2649

Appalachian

3172 (56.0%)

877 (58.3%)

Central

2049 (36.2%)

512 (34.0%)

Delta/Western

440 (7.8%)

115 (7.6%)

Angina

100 (1.8%)

97 (6.4%)

<.0001

Cereb. Disease

109 (1.9%)

106 (7.0%)

<.0001

1009 (17.8%)

464 (30.9%)

<.0001

165 (2.9%)

149 (9.9%)

<.0001

38 (0.7%)

35 (2.3%)

<.0001

254 (4.5%)

333 (22.1%)

<.0001

681 (12.0%)

483 (32.1%)

<.0001

1280 (22.6%)

686 (45.6%)

<.0001

Hypercholestrol.

268 (4.7%)

150 (10.0%)

<.0001

Osteoarthritis

376 (6.6%)

174 (11.6%)

<.0001

Previous MI

65 (1.1%)

112 (7.4%)

<.0001

Rheumatoid Arth.

83 (1.5%)

40 (2.7%)

0.0015

Anticoagulants

211 (3.7%)

220 (14.6%)

<.0001

Beta-Blockers

681 (12.0%)

321 (21.3%)

<.0001

Statins

792 (14.0%)

490 (32.6%)

<.0001

561 (9.9%)

308 (20.5%)

<.0001

973 (17.2%)

505 (33.6%)

<.0001

1026 (18.1%)

469 (31.2%)

<.0001

COPD
Cong. Heart Failure
Coagulopathy
Coron. Revascul.
Diabetes
Hypertension

C-C Blockers
ACE/ARB
Diuretics

1. All percentages are column percentages
2. Missing observations are not included in the frequency calculations
3. Comorbid conditions were identified using the Charlson and Elixhauser Indices
4. Concomitant medications were identified using active ingredients and NDC codes
5. Cereb. = Cerebrovascular, Cong. = Congestive, Coron. = Coronary, Hypercholestrol. =
Hypercholesterolemia, Arth. = Arthritis

Conditional logistic regression was used to model the sampled data including all
variables in tables 4.3 and 4.4, continuous use and duration of exposure with the exception of
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those used for matching in the incident density sampling and age. The unadjusted and adjusted
results are presented in table 4.5.
Table 4.4 Characteristics of the MI cases and matched controls from the base
population by exposure
COX2

COX1

(N=1869)

(N=5296)

NMI
(N = 1449)

MI
(N = 420)

NMI
(N = 4212)

MI
(N = 1084)

Gender
Female

766 (52.9%)

246 (58.6%)

2297 (54.5%)

545 (50.3%)

White

1203 (83.0%)

351 (83.6%)

3462 (82.2%)

872 (80.4%)

Black

53 (3.7%)

17 (4.0%)

346 (8.2%)

80 (7.4%)

Other

193 (13.3%)

52 (12.4%)

404 (9.6%)

132 (12.2%)

30-<40

452 (31.2%)

69 (16.4%)

1853 (44.0%)

185 (17.1%)

40-<50

501 (34.6%)

132 (31.4%)

1280 (30.4%)

329 (30.4%)

50-<60

406 (28.0%)

171 (40.7%)

951 (22.6%)

487 (44.9%)

60-<65

90 (6.2%)

48 (11.4%)

128 (3.0%)

83 (7.7%)

Appalachian

983 (67.8%)

290 (69.0%)

2189 (52.0%)

587 (54.2%)

Central

351 (24.2%)

103 (24.5%)

1698 (40.3%)

409 (37.7%)

115 (7.9%)

27 (6.4%)

325 (7.7%)

88 (8.1%)

Angina

35 (2.4%)

33 (7.9%)

65 (1.5%)

64 (5.9%)

Cereb. Disease

31 (2.1%)

30 (7.1%)

78 (1.9%)

76 (7.0%)

272 (18.8%)

144 (34.3%)

737 (17.5%)

320 (29.5%)

Cong. Heart Failure

47 (3.2%)

45 (10.7%)

118 (2.8%)

104 (9.6%)

Coagulopathy

12 (0.8%)

15 (3.6%)

26 (0.6%)

20 (1.8%)

Coron. Revascul.

79 (5.5%)

103 (24.5%)

175 (4.2%)

230 (21.2%)

Diabetes

183 (12.6%)

125 (29.8%)

498 (11.8%)

358 (33.0%)

Hypertension

354 (24.4%)

196 (46.7%)

926 (22.0%)

490 (45.2%)

78 (5.4%)

55 (13.1%)

190 (4.5%)

95 (8.8%)

Race

Age

Region

Delta/Western

COPD

Hypercholestrol.
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Table 4.4, continued
112 (7.7%)

55 (13.1%)

264 (6.3%)

119 (11.0%)

Previous MI

22 (1.5%)

27 (6.4%)

43 (1.0%)

85 (7.8%)

Rheumatoid Arth.

26 (1.8%)

16 (3.8%)

57 (1.4%)

24 (2.2%)

Anticoagulants

66 (4.6%)

46 (11.0%)

145 (3.4%)

174 (16.1%)

Beta-Blockers

200 (13.8%)

92 (21.9%)

481 (11.4%)

229 (21.1%)

Statins

235 (16.2%)

140 (33.3%)

557 (13.2%)

350 (32.3%)

C-C Blockers

208 (14.4%)

87 (20.7%)

353 (8.4%)

221 (20.4%)

ACE/ARB

299 (20.6%)

128 (30.5%)

674 (16.0%)

377 (34.8%)

Diuretics

315 (21.7%)

133 (31.7%)

711 (16.9%)

336 (31.0%)

Osteoarthritis

1. All percentages are column percentages
2. Missing observations are not included in the frequency calculations
3. Comorbidities were identified using the Charlson and Elixhauser comorbidities
4. Concomitant medications were identified using active ingredients and NDC codes
5. Cereb. = Cerebrovascular, Cong. = Congestive, Coron. = Coronary, Hypercholestrol. =
Hypercholesterolemia, Arth. = Arthritis

Table 4.5 Result for the Conditional Logistic Regression model
Unadjusted OR (95% CI) Adjusted OR (95% CI)
COX-2 1.116(0.982, 1.270)
COX-1

Ref

1.138(0.983, 1.318)
Ref

1. Models adjusted for region, angina, cerebrovascular disease, COPD, congestive heart
failure, coagulopathy, coronary revascularization, diabetes, hypertension,
hypercholesterolemia, osteoarthritis, previous MI, rheumatoid arthritis, anticoagulants,
beta-blockers, statins, calcium channel blockers, ACE/ARB, diuretics, continuous use and
duration of exposure

Though exposure to COX-2 presented an increased odds for MI when compared to COX1 and accounting for the risk factors listed above, this risk was not statistically significant in both
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the unadjusted and adjusted models. The adjusted and unadjusted odds ratios with their
associated CIs were 1.116(0.982, 1.270) and 1.138 (0.983, 1.318) respectively
Table 4.6 Unadjusted and adjusted OR Estimates for Covariates
Unadjusted OR
(95% CI)

Adjusted OR
(95% CI)

Region

1.037(0.924, 1.164) 1.161(1.019, 1.324)

Angina

3.395(2.571, 4.483) 0.975(0.686, 1.386)

Cereb. Disease

3.535(2.707, 4.615) 1.575(1.142, 2.173)

COPD

2.109(1.855, 2.398) 1.426(1.228, 1.655)

Cong. Heart Failure 4.418(3.486, 5.598) 1.118(0.839, 1.490)
Coagulopathy

2.593(1.694, 3.967) 1.236(0.721, 2.117)

Coron. Revascul.

5.465(4.589, 6.509) 2.265(1.782, 2.879)

Diabetes

3.596(3.136, 4.125) 2.085(1.774, 2.450)

Hypertension

2.828(2.506, 3.193) 1.322(1.126, 1.552)

Hypercholestrol.

2.235(1.816, 2.749) 0.866(0.676, 1.111)

Osteoarthritis

1.849(1.532, 2.232) 1.139(0.919, 1.411)

Previous MI

6.960(5.098, 9.502) 1.668(1.150, 2.419)

Rheumatoid Arth.

1.456(1.009, 2.101) 1.698(1.124, 2.566)

Anticoagulants

3.600(2.982, 4.347) 1.582(1.233, 2.030)

Beta-Blockers

2.053(1.772, 2.380) 1.035(0.869, 1.234)

Statins

2.947(2.584,3.361) 1.501(1.276, 1.765)

C-C Blockers

2.207(1.898, 2.566) 1.367(1.141, 1.638)

ACE/ARB

2.469(2.174, 2.804) 1.108(0.939, 1.307)

Diuretics

2.114(1.857, 2.405) 1.048(0.890, 1.234)

Continuous Use

1.566(1.396, 1.757) 1.598(1.379, 1.851)

1. Cereb. = Cerebrovascular, Cong. = Congestive, Coron. = Coronary, Hypercholestrol. =
Hypercholesterolemia, Arth. = Arthritis

Model fit statistics were evaluated for this model. Additionally, the adjusted model was
evaluated for multi-collinearity of the variables used in the model. The VIFs for all the variables
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used were evaluated and found to be small (less than 2) and within the accepted range to not
worry about multi-collinearity (greater than 5 or 10).
Table 4.6 lists the unadjusted and adjusted odds ratios for the covariates used in the model.
Region and continuous use were also evaluated as these were new variables in this study.
Region was significantly associated with risk of MI in the Kentucky Medicaid population exposed
to NSAIDs. Patients in Appalachia had significantly increased odds for MI compared to those in
the other two regions combined and accounting for all risk factors in this study (1.161[1.019,
1.324]). Continuous use was also significantly associated with risk of MI. Patients in the
continuous use group had significantly increased odds for MI compared to those in the sporadic
use group and accounting for all risk factors (1.598 [1.379, 1.851]). Most of the other comorbid
conditions and concomitant medications were also significantly associated with MI risk with the
exception of angina, congestive heart failure, hypercholesterolemia, osteoarthritis, betablockers, ACE inhibitors and diuretics.
Age at initiation was considered an effect modifier to see how the risk for MI varied for
the different age groups and the model above was done for the different age groups. The
unadjusted and adjusted ORs for the models are presented in table 4.7. Exposure to COX-2 was
not significantly different from exposure to COX-1 in risk for MI for all of the age groups with the
exception of the 30-40 year olds where both the unadjusted and adjusted results showed
significant increased risk for MI with exposure to COX-2 compared to COX-1. The adjusted and
unadjusted results with their associated CI for the 30-40 year group were 1.657 (1.201, 2.285)
and 1.600 (1.082, 2.367) respectively. In general, odds for MI with exposure to COX-2 compared
to COX-1 decreased with increase in age.
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Table 4.7 Results of the conditional logistic regression by Age group
Age Group
N
Unadjusted OR(95% CI) Adjusted OR(95% CI)
All
1504
0.982 (0.865, 1.115)
0.975 (0.848, 1.122)
30-<40
254
1.657 (1.201, 2.285)
1.600 (1.082, 2.367)
40-<50
461
1.178 (0.939, 1.477)
1.177 (0.914, 1.516)
50-<60
658
0.736 (0.607, 0.892)
0.729 (0.590, 0.901)
60-<65
131
0.964 (0.642, 1.448)
0.934 (0.569, 1.531)
1. Models adjusted for region, angina, cerebrovascular disease, COPD, congestive heart
failure, coagulopathy, coronary revascularization, diabetes, hypertension,
hypercholesterolemia, osteoarthritis, previous MI, rheumatoid arthritis, anticoagulants,
beta-blockers, statins, calcium channel blockers, ACE/ARB, diuretics, continuous use and
duration of exposure

The effect of switching from one class of medication to the other was also considered as
53% of patients in the original cohort switched between medication classes. Switching was
considered comparing the two possible switch groups and those who were only on COX-2s to
those who were only on COX-1s. Among those who switched there was not a significant
difference in risk for MI between the two possible switches (COX-1-2 and COX-2-1) when
compared to patients who had only taken COX-1s. The unadjusted and adjusted ORs for those
who switched from COX-2-1 compared to those who only took COX-1 were 1.040(0.882, 1.226)
and 1.104(0.915, 1.331) respectively. The unadjusted and adjusted ORs for those who switched
from COX-1-2 were 0.810(0.696, 0.942) and 0.947(0.800, 1.122) respectively. COX-2 only users
presented a marginally significant increased risk for MI when compared to COX-1 only users. The
unadjusted and adjusted risks were 1.208 (1.014, 1.430) and 1.221(1.003, 1.485) respectively.
Table 4.8 presents the results.
We conducted sensitivity analysis to see the differences in the population that was used
for the study and those excluded. The results are presented in table 4.9. The two populations
were similar in their demographic information and concomitant medication use with
comparable rates. There were some differences in the MI risk factors. This difference might be
attributed to the fact that we did not have time to collect this information since it was collected
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at baseline. However the MI rates in two groups did not differ significantly. The MI rates in the
included and excluded populations were 1.16% and 1.40% respectively.

Table 4.8 The effect of Switching
Switch
Unadjusted OR(95% CI) Adjusted OR(95% CI)
COX-2-1
1.040 (0.882, 1.226)
1.104 (0.915, 1.331)
COX-1-2
0.810 (0.696, 0.942)
0.947 (0.800, 1.122)
COX-2 Only
1.208 (1.014, 1.438)
1.221 (1.003, 1.485)
COX-1 Only
1.000
1.000
1. Models adjusted for region, angina, cerebrovascular disease, COPD, congestive heart
failure, coagulopathy, coronary revascularization, diabetes, hypertension,
hypercholesterolemia, osteoarthritis, previous MI, rheumatoid arthritis, anticoagulants,
beta-blockers, statins, calcium channel blockers, ACE/ARB, diuretics, continuous use and
duration of exposure

Table 4.9 Characteristics of the Included and Excluded populations
Included
Participants
(N = 129277)

Excluded
Participants
(N = 102836)

Gender
Female

87111 (67.4%) 70649 (68.7%)

Race
White

105983 (82.0%) 86054 (83.7%)

Black

12320 (9.5%)

8298 (8.1%)

Other

10974 (8.5%)

8484 (8.3%)

Age
30-<40

63611 (49.2%) 45437 (44.2%)

40-<50

32616 (25.2%) 29706 (28.9%)

50-<60

24484 (18.9%) 21073 (20.5%)

60-<65

8566 (6.6%)

6620 (6.4%)

Region
Appalachian

64479 (49.9%) 54214 (52.7%)
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Table 4.9, continued
Central
Delta/Western

52863 (40.9%) 39125 (38.0%)
11931 (9.2%)

9493 (9.2%)

Angina

2127 (1.6%)

907 (0.9%)

Cereb. Disease

2675 (2.1%)

1104 (1.1%)

21667 (16.8%)

9099 (8.8%)

Cong. Heart Failure

3349 (2.6%)

1256 (1.2%)

Coagulopathy

1145 (0.9%)

391 (0.4%)

Coron. Revascul.

5700 (4.4%)

2184 (2.1%)

Diabetes

14951 (11.6%)

6469 (6.3%)

Hypertension

28842 (22.3%) 12394 (12.1%)

COPD

Hypercholesterol.
MI

5389 (4.2%)
1504 (1.16%)

1900 (1.8%)
1437 (1.40%)

Osteoarthritis

8020 (6.2%)

3798 (3.7%)

Previous MI

1524 (1.2%)

621 (0.6%)

Rheumatoid Arth.

2313 (1.8%)

1163 (1.1%)

Anticoagulants

5326 (4.1%)

3249 (3.2%)

Beta-Blockers

13656 (10.6%) 10595 (10.3%)

Statins

16476 (12.7%) 11762 (11.4%)

C-C Blockers

11591 (9.0%) 10706 (10.4%)

ACE/ARB

21177 (16.4%) 16284 (15.8%)

Diuretics

22657 (17.5%) 19122 (18.6%)

1. All percentages are column percentages
2. Missing observations are not included in the frequency calculations
3. Comorbidities were identified using the Charlson and Elixhauser comorbidities
4. Concomitant medications were identified using active ingredients and NDC codes
5. Cereb. = Cerebrovascular, Cong. = Congestive, Coron. = Coronary, Hypercholestrol. =
Hypercholesterolemia, Arth. = Arthritis
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Discussion
The data from this nested case-control study showed that the overall odds of MI did not
differ significantly between those taking COX-1 and COX-2s in a young cardiovascular disease
burdened Medicaid population. This study was designed to investigate the risk of MI in patients
taking COX-2 compared to COX-1. This result is consistent with hypotheses which have
questioned a class effect between classes of NSAIDs. Antman et al (2005) raised the question
about a true class effect in discussing the risks of NSAIDs. Furthermore, several studies have
showed that there was no difference in risk of MI when individual COX-2 drugs were compared
with their COX-1 counterparts (Back, Yin, & Ingelsson, 2012; Stephen E Kimmel et al., 2005;
Mamdani et al., 2003).
However, this study is different because it carried out a class comparison in a younger
(30-64 years) post-market population taking into consideration switching patterns and
differentiating between continuous and sporadic users. It is important from a clinical
perspective as patients need to be monitored for adverse events both during exposure to the
drugs and after exposure. Of the 1504 cases, 658(43.75%) has an MI after their last exposure to
the drugs. Furthermore, patients have to be considered in the pattern of their adherence which
is sometimes different from the pattern of adherence that is followed during clinical trials. This
study investigates that by taking into consideration the switching patterns of the patients.
Even though there was not a significant difference in risk for MI with exposure to COX-2
was compared to COX-1 we think there is a clinical difference. We calculated the numbers
needed to harm which show that for every 50 patients between the age of 30 and 65 years
taking a COX-2 one additional patient will have an MI in the time frame. Given the high
prevalence of the use of these drugs in the general population the number of patients needed
to harm could have considerable implications for public health.
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This inter-class comparison is important because after the removal of the coxibs from
the market the remaining NSAIDs were made to contain a blanket warning about the
cardiovascular risk with regards to their use. Up until recently, the FDA is still involved in
discussions with researchers as to whether these warnings are still relevant and should still stay
on the boxes (Gever, 2014). This study shows that a class warning may be relevant for the class
of drugs used within certain age groups. As such continuous monitoring of this risk should be
done from time to time to see where we are at.
While there was no overall difference in risk for MI between the NSAID classes, there
was a difference in risk when switching patterns were considered and for certain age groups.
Age at initiation was investigated as a potential effect modifier. Patients in the 30-40 year old
group presented a significantly increased risk for MI when COX-2 users were compared to COX-1
users. The other age groups did not show a significant difference in risk for MI between COX-1s
and COX-2s. Patients in the 30-40 year old group presented a 60% increased risk while patients
in the 40-50 year old group presented an 18% increased risk for MI with the former been
significant and latter not significant.
Switching from one class of medication to the other was considered as more than 53%
of the cohort used for this study had switched between a COX-1 and a COX-2 or vice versa.
Among those who switched in the two possible groups there was not a difference in odds when
the possible switches were compared to those only on COX-1s during their time in the study.
However, there was a marginally significant increased risk for MI when COX-2 only users were
compared to COX-1 only users. While there was not an overall difference in risk when
comparing Cox-2 to COX-1 NSAIDs, this study found a significant difference in risk when COX-2
only users were compared to COX-1 only users. COX-2 only users presented a 22% increase in
risk for MI when compared to COX-1 only users.
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Switching medications is a common phenomenon in the general population. Patients
switch medications for different reasons. One of these reasons is reactions to the medication
they are taking. A possible explanation for the increased risk is that those who are switching are
already sicker to begin with compared to those who did not. Further research into switching
patterns between NSAIDs medications and the possible ramifications is warranted.
Region and continuous use were also evaluated in this study and found to be
significantly associated with risk for MI in the Kentucky Medicaid population. Patients in the
Appalachian region had significantly increased risk when compared to those in the other two
regions. Patients in the continuous use group had significantly increased risk when compared to
those in the sporadic use group. This highlights the fact that the disease burden usually seen in
Appalachia is also present in the Medicaid population exposed to NSAIDs. The combination of
chronic continuous drug use and region could have potential public health implications if not
monitored adequately.
The pattern of NSAID prescriptions in this cohort mirrors the rest of the country in the
popularity and decline of the coxibs. The decline started around 2002 which corresponds to the
time when research studies highlighting the cardiovascular effects of NSAIDs were being
published. In the last few years the new users initiation/new prescriptions in Kentucky Medicaid
has leveled out.
Understanding the cardiovascular risk associated with NSAID use and the factors
associated with said risk is essential given their widespread use in the general population. This is
especially important in light of recent health care laws where it is anticipated that more people
will be exposed to these medications. An understanding of exposure and risk factors in a
younger population will help public health practitioners in preparing for an older population.

67

Additionally, understanding these factors in a heavily burdened population would enable
practitioners to be able to assess this scenario and come up with more preventative measures.
Furthermore, it should be taken into consideration that the cohort was limited to those
less than 65 years to accommodate for loss of information due to the initiation of Medicare part
D and allow for uniform cohort enrollment over the duration of the study. However, even
amongst this young cohort (30-64 years), there was a heavy use of NSAIDs. This increased use
warranted a need for the study of the MI risk associated with NSAID use in this population.
A major strength of this study is the large sample size in the original cohort. This allowed
for the use of the new user design with a large enough sample left for the nested case-control
analysis. However this could also be a limitation because if not handled adequately there is the
potential for meaningful associations to be lost in the milieu of data. With very large sample
sizes most associations tend to be significant due to the law of large numbers. Secondly, this
study has a long window of available data. This study had twelve years of Kentucky Medicaid
data which allowed for the possibility of longer follow-ups. The average length of follow-up for
this study was 3.9 years which is more than most other studies in this area. Thirdly, this study
takes into consideration switching between medication classes, which is a very common
phenomenon among patients as shown by the data.
There are several limitations to this study. A secondary database was used to define
both exposure and outcome. This could lead to possible misclassification of both exposure and
outcome due to missing information. There was also the lack of information on OTC medication.
However the effect of this is expected to be low given the comprehensive nature of the
program. Although some of the NSAIDS could be obtained over the counter, the fact that the copay was low was an economic incentive to purchase the drugs through the program. As such, it
is believed that this will not have a significant effect on the results as most patients will want to
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maximize the financial benefits of the program. Regardless, some exposure misclassification is
expected and this will probably bias the results towards the null effect.
Another limitation of this study is the lack of information on smoking –identified as
potentially the largest lifestyle confounder-, obesity and other lifestyle factors. However, some
studies have shown that these lifestyle factors were not differentially distributed by exposure
group. We used COPD as a proxy for smoking and found no differential distribution between the
exposure groups in the controls (27.4% vs 23.9%). Additionally, it has been hypothesized that
these lifestyle factors affect medical risk factors such as hypertension and angina which are both
accounted for in this study (Ray, Stein, Hall, et al., 2002).
Finally, loss of patients due to use of the new users design could also be a limitation.
However, this was done to curb the biases that are inherent in studies of this nature that use
prevalent users.
This study did not show a significantly overall increased risk for MI when NSAID COX-2
users are compared to COX-1 users in a nested cohort of the Kentucky Medicaid population.
However when the analysis was done for the different age groups there was a significantly
increased risk for MI in the 30-40 year old group even though they account for 16.9% of the
total number of cases. Further studies are needed to ascertain this relationship especially given
the increased risk of cardiovascular diseases in this population and the importance of risk factors
that further increase said risk. More research is needed for methods to identify further risk of
exposure in populations that are already at increased risk for certain outcomes especially in
large databases.
This study also showed that the increased risk from exposure to COX-2 NSAIDs that had
been posited in older populations is also present in some younger populations. The youngest
age group studied (30-<40 years) presented significantly increased MI risk for COX-2 users
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compared to COX-1 users. This has significant public health consequences especially when taken
in light of the present health care landscape and the fact that cardiovascular risk increases with
age. Although this is an observational study, the evidence it presents in combination with the
literature highlights the cardiovascular risk of COX-2s especially when compared to COX-1s and
investigated in a heavily burdened population. Given the wide spread use of NSAIDs in the
general population, extreme caution should continue to be taken especially in those patients
who already present risk factors for cardiovascular diseases.
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Chapter Five
Comparison of Meloxicam with Celecoxib and Naproxen
Introduction
Meloxicam is one of the NSAIDs that has been less studied compared to its counterparts
because of low use in some populations (Levesque et al., 2005; McGettigan & Henry, 2011). In
the Kentucky Medicaid population there is an increased prescription of the drug especially
following the removal of rofecoxib and valdecoxib from the US market (Figure 3.4). They were
withdrawn in 2004 and 2005 respectively due to adverse events. It is assumed that this
increased prescription indicates increased use in the same population. It is hypothesized that
this drug has replaced the popularity of those withdrawn that used to be more popular. This
phenomenon was also seen in Australia where meloxicam replaced both rofecoxib and celecoxib
after the publicity about their adverse events (Barozzi & Tett, 2007; McGettigan & Henry, 2006).
Meloxicam has been hypothesized to have a dual nature with regards to NSAID classification. In
the literature, it has been classified as both a COX-1 and a COX-2 (Antman et al., 2005; Graham,
2006; Moodley, 2008).
Celecoxib was one of the first coxibs released in the US by Pfizer (Chan et al., 2006;
Kearney et al., 2006). While it is a certified COX-2, its effect on cardiovascular risk varies across
the literature. It was heavily promoted and marketed for its less harmful GI adverse side effect.
It is one of the most widely prescribed NSAIDs in the US (Graham, 2006). Additionally, it has
been on the market longer and has the largest body of evidence of use to be studied compared
to the other COX-2s.
The APC trial was instrumental in uncovering the cardiovascular risk of celecoxib. This
study found that patients exposed to celecoxib had an increased risk for cardiovascular diseases
and was halted prematurely as a result of the findings (S. D. Solomon et al., 2005). This study
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found an increase in death from cardiovascular diseases with use of celecoxib when compared
to placebo (hazard ratio=3.4[1.4, 7.8]). MI was one of the cardiovascular diseases studied.
The CLASS study compared celecoxib with other NSAIDs in patients with osteoarthritis
and rheumatoid arthritis and found no difference in cardiovascular events, including MIs
(Bresalier et al., 2005; Cannon et al., 2006; Silverstein et al., 2000). Additionally, this was a
pooled analysis that included results from several trials including the SUCCESS-1 (Singh et al.,
2006). There was no difference in the incidence of cardiovascular events between celecoxib and
other NSAIDs- 0.3% vs 0.3%.
Several other studies in different countries have highlighted the cardiovascular risk of
celecoxib in different comparisons (Graham et al., 2005; Johnsen et al., 2005). However, there
are other studies that have not found an increased risk (McGettigan & Henry, 2006). In a study
of elderly patients, celecoxib was not found to have increased MI risk compared to controls
(Mamdani et al., 2003). In a systematic review of 16 observational studies, a significantly
increased risk for MI was not found with use of celecoxib (Hernandez-Diaz et al., 2006).
After the other coxibs were withdrawn from the market, the FDA allowed celecoxib to
remain on the market and requested its labeling together with 18 other tNSAIDS describe the
increased risk of cardiovascular events (Antman et al., 2005; FDA, 2005). Celecoxib continues to
be widely used despite studies showing an increased risk of MI associated with the drug
(Kearney et al., 2006).
Naproxen is one of the most prescribed NSAIDs worldwide (Patrono & Baigent, 2014). It
has been hypothesized to be a stronger antiplatelet agent when compared to other NSAIDs
(Rahme et al., 2002). It is a certified COX-1 and the safest of all NSAIDs with regards to
cardiovascular safety according to the literature. It has been posited to have a cardio-protective
effect when compared to other NSAIDs (Bombardier et al., 2000; Garcia Rodriguez & Gonzalez-
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Perez, 2005; Juni et al., 2004; Topol, 2004). While this is debatable, at the very least it has a
consistent reduced risk for cardiovascular adverse events when compared to the other NSAIDs
(Hernandez-Diaz et al., 2006).
The VIGOR Trial compared rofecoxib with naproxen in patients with rheumatoid arthritis
and found rofecoxib associated with a significant risk of cardiovascular events (0.1% versus
0.4%) (Bombardier et al., 2000). However, it was not confirmed whether this was due to a
protective effect of naproxen, an increased risk from rofecoxib or a combination of both.
In comparisons with no NSAID use, naproxen has been found to have a significantly
increased risk for MI (Graham et al., 2005). The adjusted odds ratio was 1.14 (1.00-1.30). A
cohort study of elderly patients older than 66 years who were dispensed selective NSAIDs,
naproxen and other NSAIDs, compared the rates of MI across groups (Mamdani et al., 2003).
Members of the cohort were identified from administrative health care data from Ontario,
Canada. This study found no significant difference in short-term MI risk for new users of
naproxen (RR=1.0[0.6-1.7]) and other NSAIDs (RR=1.2[0.9-1.4]). Several other studies have
endorsed the reduced risk of MI with exposure to naproxen (Juni et al., 2004; Kearney et al.,
2006; McGettigan & Henry, 2006).
Several researchers have called for further studies to identity which NSAIDs minimize
overall burden of adverse cardiovascular risk (Kearney et al., 2006; S. E. Kimmel et al., 2004;
Stephen E Kimmel et al., 2005; Moodley, 2008). Cardiovascular disease is a leading risk factor for
death worldwide (Alwan, 2011). As a result, continuous monitoring of the NSAID-MI relationship
is needed because an agent that potentially affects such an important risk factor poses
considerable public health consequences.
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This study aims to assess the cardiovascular safety of meloxicam, celecoxib and
naproxen, with a 12 year follow-up, by comparing them with no exposure and considering time
at risk for MI.
Methods
Study overview
A retrospective cohort study was conducted to examine the risk of MI among younger
(30-64 years) Kentucky Medicaid enrollees who were prescribed meloxicam, celecoxib and
naproxen between January 1st 2000 and December 31st 2012. Only patients with these three
prescriptions were selected for entry into the cohort. Within this cohort we conducted a nested
case-control study. The primary objective of this study was to compare MI cases to controls
between users of meloxicam, celecoxib and naproxen compared to patients with no exposure.
Data Source
Data for this study included administrative and prescription claims of Kentucky Medicaid
linked with hospital discharge information and death dates collected between January 1st 2000
and December 31st 2012. Enrollment and patient demographic information were included in an
enrollment file. Prescription files contained dates, drug name, quantity, dose and days of supply.
Hospital and outpatient files included admission and discharge dates for hospitalizations,
outpatient and emergency department visits. Diagnoses associated with hospitalizations and
visits were identified using ICD-9-CM codes.
Subjects included persons aged 30 to 64 years enrolled in Medicaid between 2000 and
2012, had demographic information and had at least one outpatient encounter or filled NSAID
prescription. We restricted patients 65 and older from entering the cohort because of the
introduction of Medicare Part D in 2006.
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Cases of MI were identified based on admission for MI as identified from hospital
discharge diagnosis codes (ICD-9-CM 410.xx) in the primary and secondary diagnoses positions
which was validated by a hospital stay of more than 2 days but less than 180 days, unless the
patient died (Roumie et al 2009, Solomon et al 2004, Petersen et al 1999). Two days was chosen
because studies have validated this algorithm for claims data ICD-9-CM diagnosis and found high
positive predictive value, specificity and sensitivity (Brouwer et al., 2013; Graham et al., 2005;
Metcalfe et al., 2013; Roumie et al., 2009; Wahl et al., 2010) .
Case-control Analysis
Cases were patients aged 30-64 years with a first MI identified in the cohort. We matched four
controls to each case by age of diagnosis, gender and race using incident density sampling. All
controls were alive and enrolled in Kentucky Medicaid at the time their matched case was
diagnosed. We derived an index date for each control, which was the date of MI for their
matched case.
A SAS macro by Richardson (2004) with some edits was used for the incidence density
sampling. For matching on age at diagnosis, race and gender, estimated probabilities were
generated using logistic regression with MI as the outcome and age, race and gender as the
inputs. The probabilities were multiplied by a hundred and rounded to the nearest whole
number to form categories which were used for matching. This was done as an alternative
method to incorporate matching using propensity scores.
Exposure classification
The exposure was the NSAID used before the index date, which was the date of MI for a
case and its matched controls. The NSAIDs of interest were meloxicam, celecoxib and naproxen.
All drugs were identified by their national drug codes (NDCs) and classified into one of the two
types using MULTUM (Multum, 2013). Patients who did not use a drug of interest before their
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index date were classified as having no exposure and formed the control group for exposure
classification. Patients were classified based on their first NSAID exposure prior to their index
date which was carried forward to the end of the study. Patients were not re-classified for claim
changes. Additionally, duration of exposure or drug use was considered by summing up the
number of days supply for the prescriptions from entry in the study till the index date. This was
then classified into five categories with a sixth category of no use for those patients who did not
use a drug before the index date. The five duration-of-drug-use categories were 0-30 days, 3190 days, 91-180 days, 180-365 days and more than 365days. Finally, patients were classified into
continuous, sporadic and non-drug user groups. Continuous use of NSAIDs was considered
consecutive prescriptions with a gap of less than 30 days between prescriptions prior to the
index date. If there were gaps of more than 30 days the patient was considered a sporadic user
and patients with no drug use prior to the index date were in the non-drug use group.
Covariates
Baseline covariates were measured prior to the index date. The study covariates
included state region of residence, co-morbid conditions and concomitant medication (other
non-NSAID medications).
Demographics
Demographic variables were identified from patient enrollment data. The enrollment
file contained the patient’s county of residence. This was used to determine Kentucky residence
as a categorical variable with options: Appalachian, Central and Delta or Western. Figure 3.2
shows the division of the state into the three regions.
Comorbid Conditions
Comorbid conditions were obtained from Medicaid medical files. The ICD-9-CM codes
were used in coding algorithms for the Elixhauser and Charlson comorbidities (Quan et al.,

76

2005). These algorithms have been validated to identify comorbidities from administrative data.
Claims data have a stipulated number of diagnoses and for Medicaid, there are up to ten
diagnoses reported. The following comorbid conditions were assessed based on the literature:
angina, cerebrovascular disease , COPD , congestive heart failure , coagulopathy , coronary
revascularization , diabetes , hypertension , hypercholesterolemia , osteoarthritis , and
rheumatoid arthritis (Baron et al., 2008; Shau et al., 2012). Table 4.1 lists the comorbid
conditions with their corresponding ICD-9-CM codes.
Concomitant medication
Several methods are used to assess disease severity in the use of claims data. The
use of concomitant medication is one such method and this was identified from the prescription
claims file. The main drug classes considered were statins, beta-blockers, anticoagulants,
calcium channel blockers, ACE inhibitor, ARB and diuretics. These were all considered based on
the literature (Cannon et al., 2006; Graham et al., 2005; Daniel H Solomon et al., 2004). Table
4.2 lists the drug classes and the medications considered in those classes. Concomitant
medications were identified using MULTUM (Multum, 2013).
Statistical Analysis
SAS 9.3 was used for both data manipulation and statistical analyses.
This paper assessed the risk of MI after use of meloxicam, celecoxib (a widely used COX2) and naproxen (a widely used COX-1) compared to no exposure using patients in the cohort.
Comparisons were presented of cases and controls in tables using frequencies and
percentages. Tables comparing cases and controls by the three different exposure groups and
no exposure were also presented to see differences by exposure for the demographic and risk
factors considered. Conditional logistic regression for matched case-control studies was used to
evaluate the association between NSAID use and MI taking into consideration confounders and
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risk factors not used for matching. Continuous use and categories for duration of exposure were
also accounted for. Due to the rareness of the outcome and the incidence density sampling, the
estimated ORs approximate the relative risk. Covariates were determined based on the
literature and the characterization of the population.
The Institutional Review Boards of the University of Kentucky (IRB Number 12-0999P2H) and the Kentucky Cabinet for Health and Family Services (CHFS-IRB-DMS-FY13-15)
approved this study.
Results
There were 149,917 patients between the ages of 30 and 64 years who were prescribed
meloxicam, celecoxib or naproxen during the study period. We identified 2,198 first cases of MI
which were matched to 8,792 controls by age at diagnosis, gender and race using incident
density sampling.
Table 5.1 shows the characteristics of the MI cases and controls. Cases and controls
were well matched on age at diagnosis, race and gender as evidenced by the non-significant pvalues showing the lack of differences in the levels of these variables.
The majority of the cases (59.6%) were from the Appalachian region as opposed to
32.6% and 7.9% from the Central and Delta regions respectively. The same pattern was repeated
for the controls with 58.8% from the Appalachian region, 33.3% from the Central region and
8.0% from the Delta. There was not a large difference in regional percentages between cases
and controls. Even though we did not match on region, the distribution of cases and controls
among the three regions was well balanced. This table also highlights the risk factors
considered. The proportion of patients with risk factors among cases is significantly higher than
controls for all of the comorbid conditions and concomitant medications. And in some cases
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there is more than a doubling or more of these proportions. For example, 23.9% of the MI cases
had a coronary revascularization compared to 5.7% of controls.

Table 5.1 Characteristics of the MI cases and matched controls
NMI
(N = 8792)

MI
(N = 2198) P-Value

Gender
Female

0.9465
4821 (54.8%) 1207 (54.9%)

Race
White

0.2732
7276 (82.8%) 1831 (83.3%)

Black

364 (4.1%)

102 (4.6%)

Other

1152 (13.1%)

265 (12.1%)

Age

0.3953

30-<40

1156 (13.1%)

263 (12.0%)

40-<50

2597 (29.5%)

675 (30.7%)

50-<60

3857 (43.9%)

973 (44.3%)

60-<65

1182 (13.4%)

287 (13.1%)

Region

0.7968

Appalachian

5167 (58.8%) 1309 (59.6%)

Central

2924 (33.3%)

716 (32.6%)

Delta/Western

701 (8.0%)

173 (7.9%)

Angina

206 (2.3%)

163 (7.4%)

<.0001

Cereb. Disease

202 (2.3%)

135 (6.1%)

<.0001

1514 (17.2%)

574 (26.1%)

<.0001

247 (2.8%)

219 (10.0%)

<.0001

67 (0.8%)

34 (1.5%)

0.0006

503 (5.7%)

525 (23.9%)

<.0001

Diabetes

1137 (12.9%)

573 (26.1%)

<.0001

Hypertension

2140 (24.3%)

813 (37.0%)

<.0001

Hypercholesterol.

447 (5.1%)

208 (9.5%)

<.0001

Osteoarthritis

687 (7.8%)

210 (9.6%)

0.0077

COPD
Cong. Heart Failure
Coagulopathy
Coron. Revascul.
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Table 5.1, continued
Rheumatoid Arth.

139 (1.6%)

50 (2.3%)

0.0252

Anticoagulants

458 (5.2%)

356 (16.2%)

<.0001

Beta-Blockers

1310 (14.9%)

506 (23.0%)

<.0001

Statins

1732 (19.7%)

761 (34.6%)

<.0001

C-C Blockers

1399 (15.9%)

483 (22.0%)

<.0001

ACE/ARB

1973 (22.4%)

740 (33.7%)

<.0001

Diuretics

2156 (24.5%)

718 (32.7%)

<.0001

1. All percentages are column percentages
2. Missing observations are not included in the frequency calculations
3. Comorbidities were identified using the Charlson and Elixhauser comorbidities
4. Concomitant medications were identified using active ingredients and NDC codes
5. Cereb. = Cerebrovascular, Cong. = Congestive, Coron. = Coronary, Hypercholesterol. =
Hypercholesterolemia, Arth. = Arthritis

Table 5.2 shows the characteristics of the cases and controls by the different exposure
groups. There were 679 (6.2%) patients exposed to meloxicam prior to their index date, 2786
(24.4%) to celecoxib, 4224 (38.4%) to naproxen and 3301 (30.0%) not exposed to any of the
three medications. The four groups almost follow the same pattern for gender, race and region.
Most of the patients in the four groups were female with the exception of the no exposure
group where females were slightly lower than males (49.7%). The pattern for race was
consistent across the groups with whites been the majority composition followed by others and
then blacks. Additionally, across all the groups most patients were from the Appalachian region
followed by the Central and Delta regions. The distribution for age at diagnosis was also similar
for the groups. The modal age group for the four exposure groups was the 50-60 years. There
was a steady increase in the percentage of patients as age increased up to the modal age group
and then there was a decline.
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Cases of MI were similarly distributed among the exposure groups with celecoxib having
a slightly higher rate (22.1%) followed by naproxen (20.3%) and then meloxicam and no
exposure with rates of 18.9% and 17.8% respectively. Meloxicam had higher or comparable
rates than celecoxib for almost all of the comorbid conditions but lower rates for the
concomitant medications considered in this study. Naproxen users had the lowest rates for all
the risk factors studied even when compared to the no exposure group.

Table 5.2 Characteristics of the MI cases and matched controls by Exposure
MEL
(N = 679)

CELE
(N = 2786)

NAP
(N = 4224)

NO EXP
(N= 3301)

Gender
Female

411 (60.5%) 1637 (58.8%) 2339 (55.4%) 1641 (49.7%)

Race
White

561 (82.6%) 2360 (84.7%) 3432 (81.3%) 2754 (83.4%)

Black

32 (4.7%)

50 (1.8%)

244 (5.8%)

140 (4.2%)

Other

86 (12.7%)

376 (13.5%)

548 (13.0%)

407 (12.3%)

30-<40

84 (12.4%)

279 (10.0%)

657 (15.6%)

399 (12.1%)

40-<50

192 (28.3%)

825 (29.6%) 1418 (33.6%)

837 (25.4%)

50-<60

340 (50.1%) 1361 (48.9%) 1827 (43.3%) 1302 (39.4%)

Age

60-<65

63 (9.3%)

321 (11.5%)

322 (7.6%)

763 (23.1%)

Region
Appalachian

403 (59.4%) 1939 (69.6%) 2313 (54.8%) 1821 (55.2%)

Central

232 (34.2%)

Delta/Western

616 (22.1%) 1596 (37.8%) 1196 (36.2%)

44 (6.5%)

231 (8.3%)

315 (7.5%)

284 (8.6%)

128 (18.9%)

625 (22.4%)

856 (20.3%)

589 (17.8%)

Angina

30 (4.4%)

65 (2.3%)

103 (2.4%)

171 (5.2%)

Cereb. Disease

21 (3.1%)

74 (2.7%)

97 (2.3%)

145 (4.4%)

142 (20.9%)

474 (17.0%)

751 (17.8%)

721 (21.8%)

MI

COPD
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Table 5.2, continued
27 (4.0%)

102 (3.7%)

135 (3.2%)

202 (6.1%)

6 (0.9%)

25 (0.9%)

30 (0.7%)

40 (1.2%

56 (8.2%)

192 (6.9%)

245 (5.8%)

535 (16.2%)

Diabetes

120 (17.7%)

392 (14.1%)

608 (14.4%)

590 (17.9%)

Hypertension

208 (30.6%)

577 (20.7%)

982 (23.2%) 1186 (35.9%)

52 (7.7%)

131 (4.7%)

207 (4.9%)

265 (8.0%)

79 (11.6%)

245 (8.8%)

280 (6.6%)

293 (8.89%)

Rheumatoid Arth.

19 (2.8%)

45 (1.6%)

56 (1.3%)

69 (2.1%)

Anticoagulants

46 (6.8%)

194 (7.0%)

210 (5.0%)

364 (11.0%)

Beta-Blockers

122 (18.0%)

495 (17.8%)

597 (14.1%)

602 (18.2%)

Statins

169 (24.9%)

623 (22.4%)

835 (19.8%)

866 (26.2%)

C-C Blockers

109 (16.1%)

568 (20.4%)

649 (15.4%)

556 (16.8%)

ACE/ARB

173 (25.5%)

697 (25.0%)

943 (22.3%)

900 (27.3%)

Diuretics

190 (28.0%)

819 (29.4%) 1001 (23.7%)

864 (26.2%)

Cong. Heart Failure
Coagulopathy
Coron. Revascul

Hypercholesterol.
Osteoarthritis

1. All percentages are column percentages
2. Missing observations are not included in the frequency calculations
3. Comorbidities were identified using the Charlson and Elixhauser comorbidities
4. Concomitant medications were identified using active ingredients and NDC codes
5. Mel= Meloxicam, Cele= Celecoxib, Nap= Naproxen, No exp=No Exposure, Cereb. =
Cerebrovascular, Cong. = Congestive, Coron. = Coronary, Hypercholestrol. =
Hypercholesterolemia, Arth. = Arthritis

Conditional logistic regression was used to model the sampled data including all
variables with the exception of those used for matching in the incident density sampling.
Duration of exposure categories and continuous use were also included in the model. The
unadjusted and adjusted results are presented in table 5.3. Exposure to meloxicam did not
present significantly increased risk for MI when compared to no exposure and accounting for
risk factors. The unadjusted and adjusted odds ratio of MI when meloxicam was compared to no
exposure were 1.10 (0.88, 1.38) and 1.26 (0.98, 1.63) respectively. The unadjusted and adjusted
odds ratio of MI when celecoxib was compared to no exposure were 1.36 (1.19, 1.55) and 1.52
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(1.26, 1.82) respectively. The unadjusted and adjusted odds ratio of MI when naproxen was
compared to no exposure were 1.20 (1.06, 1.37) and 1.47 (1.24, 1.73) respectively. Celecoxib
and naproxen presented significantly increased risks for MI when compared to no exposure for
both the adjusted and unadjusted estimates. Meloxicam though presenting an increased risk
was not significantly different from no exposure. The estimates for meloxicam’s risk for MI are
lower than both celecoxib and naproxen in the unadjusted and adjusted scenarios.

Table 5.3 Result for the Conditional Logistic Regression model comparing Meloxicam,
Celecoxib and Naproxen to No Exposure
Unadjusted OR (95% CI)
Adjusted OR (95% CI)
Meloxicam

1.10 (0.88, 1.38)

1.26 (0.98, 1.63)

Celecoxib

1.36 (1.19, 1.55)

1.52 (1.26, 1.82)

Naproxen

1.20 (1.06, 1.37)

1.47 (1.24, 1.73)

No Exposure

Ref

Ref

1. Models adjusted for region, angina, cerebrovascular disease, COPD, congestive heart
failure, coagulopathy, coronary revascularization, diabetes, hypertension,
hypercholesterolemia, osteoarthritis, rheumatoid arthritis, anticoagulants, betablockers, statins, calcium channel blockers, ACE/ARB, diuretics, continuous use and
duration of exposure

We investigated the risk for MI for different categories of duration of use compared to
no use. The results are presented in table 5.4. There was a consistent, though not always
significant, increased risk for MI across all duration of use groups when compared with no use.
The unadjusted results for the first two duration categories were not significant but all the
adjusted estimates were significant at the 5% level. In general, the risk increased as usage
increased in both the adjusted and unadjusted analysis with the exception of a small dip for the
31-90 days category for the adjusted estimates.
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Table 5.4 Duration of Exposure and Risk for MI
Unadjusted OR (95% CI)
Adjusted OR (95% CI)
0-30 days

1.11 (0.96, 1.28)

1.47 (1.24, 1.73)

31-90 days

1.15 (0.98, 1.35)

1.39 (1.14, 1.70)

91-180 days

1.30 (1.09, 1.55)

1.63 (1.32, 2.01)

181-365 days

1.41 (1.18, 1.68)

1.77 (1.43, 2.18)

Greater than 365 days

1.54 (1.32, 1.80)

2.05 (1.68, 2.49)

No Exposure

Ref

Ref

1. Models adjusted for region, angina, cerebrovascular disease, COPD, congestive heart
failure, coagulopathy, coronary revascularization, diabetes, hypertension,
hypercholesterolemia, osteoarthritis, rheumatoid arthritis, anticoagulants, betablockers, statins, calcium channel blockers, ACE/ARB, diuretics, continuous use and
duration of exposure

Discussion
The data from this nested case-control study showed that there is a difference in risk of
MI when meloxicam, celecoxib and naproxen are compared to no exposure. There is an
apparent hierarchy in risk with celecoxib showing the most risk followed by naproxen and then
meloxicam. This was an observational study with young patients 30-64 years from a population
heavily burdened with cardiovascular diseases. In the unadjusted and adjusted analysis
meloxicam was not significantly different from no exposure in risk for MI but celecoxib and
naproxen were. However, there is quite considerable overlap between the confidence intervals
for the MI risks of meloxicam, celecoxib and naproxen when compared to no exposure.
This study suggests a hierarchy in risk of MI for different NSAIDs. This study puts
meloxicam below naproxen and celecoxib in terms of MI risk. In that regard, this study suggests
that meloxicam is more likely a COX-1 drug than a COX-2 possibly because of reduced COX-2
selectivity. An understanding of meloxicam is important because in some populations (including
the one studied) it has replaced other NSAIDs in terms of prescription popularity following the
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bad publicity concerning cardiovascular adverse effects. In chapter three, the popularity of
meloxicam to surpass the other NSAIDs was seen. This study is consistent with two other studies
that have found no significant increased risk for MI with exposure to meloxicam when compared
with non-use (Garcia Rodriguez et al., 2004; Levesque et al., 2005). However, it should be noted
that meloxicam had the smallest number of cases of all the exposure groups studied.
This is an observational study and is therefore at risk of bias and possible confounding.
However, this analysis accounted for many potential confounders including, comorbidities and
concomitant medications and we expect that this may have reduced the impact of any such
occurrences. The ability to account for so many potential confounders was made possible by the
large sample size of the cohort.
The cases and controls were well matched on race, gender and age of diagnosis, and
accounting for total duration on drugs categories and whether the exposure was continuous or
sporadic compared to no exposure. The measure of our outcome (whether patients had an MI
or not), as recorded by ICD-9-CM codes has been validated by several studies and found to have
high sensitivity, specificity and positive predictive value. Dose was not analyzed because this can
vary from day to day depending on the levels of pain that the patient is experiencing (HippisleyCox & Coupland, 2005). Duration of exposure served as a proxy for cumulative dose.
Additionally, rofecoxib was the coxib that has been consistently shown to have a dose response
relationship and it is not included in this study. Celecoxib has been identified as having no dose
response relationship (Hernandez-Diaz et al, 2006; Levesque et al, 2005).
While this is an observational study and is not conclusive, our results suggest that meloxicam is
more of a COX-1 than a COX-2 and adds to the literature in terms of classifying this drug that has
been dually classified for a long time. Additionally, this study adds to the body of literature
about meloxicam which is very scarce.
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Chapter Six
Discussion & Conclusion
This chapter provides a summary and discussion of the conclusions of the other
chapters in this dissertation. It also includes individual and public health implications, strengths
and limitations and recommendations for future research. There were four other chapters
presented in this dissertation apart from the introduction. These include:
1. A literature review of the NSAIDs-MI association
2. An understanding of NSAIDs prescription practices in the Kentucky Medicaid population
3. A comparison of COX-1 and COX-2 exposure in the Kentucky Medicaid population with
regards to risk of MI; and
4. A comparison of Meloxicam, Celecoxib and Naproxen to no exposure for risk of MI
Chapter two was a comprehensive literature review that focused on the different studies
that have been employed in the study of the NSAIDs-MI association and their findings. The
purpose of this review was to provide a framework of the studies that have been employed and
the methods used in these different studies. This review showed that the main study types that
have been employed were clinical trials, case-control and retrospective cohort studies, nested
case-control studies and meta-analysis. There was not a consensus in the direction of the
NSAIDs-MI relationship across studies. Some studies found increased risks for MI when certain
NSAIDs were compared to others or placebo use, some found a protective effect and some
found no effect. These differing results have aided the controversy in the study of this
relationship. Additionally, a number of studies have employed electronic databases in the study
of the NSAID-MI association. Furthermore, most of the studies have employed older populations
with a short term follow-up. There was a shortage of studies that had a long term follow-up and
employed a younger cohort of patients. Finally, there was a limited number of studies that had
explored the cardiovascular risk of meloxicam.
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In chapter three, the purpose was to understand the prescription of NSAIDs in the Kentucky
Medicaid population. Post-market populations tend to be different from clinical trial populations
in terms of adherence to prescription medications. This study found that the trends in the
prescription of NSAIDs have changed over the years with some medications gaining popularity
as their counterparts loose popularity. Specifically, the coxibs have declined in prescription
popularity while other drugs like meloxicam have increased in popularity. This trend has been
identified by other studies (Barozzi & Tett, 2007). Secondly, this study found that patients did
not always adhere to their medication prescriptions. There were gaps between prescriptions. As
a result, these gaps were taken into consideration in the models used. Patients with gaps less
than 30 days were considered to be continuous users based on the distribution of the
prescription gaps. Also, it highlighted the prevalence of switching between medications which
was taken into consideration in the analysis. To our knowledge no other study has done this.
Thirdly, this study found that new use of NSAIDs was gradually increasing in the Kentucky
Medicaid population due to the increase in use of young users. Fourthly, the trends in use of
NSAIDs in the study population mirrored that of the general US population. The increase in the
popularity of the coxibs and their subsequent decrease was seen.
Finally, this study showed the importance of region as a proxy for underlying socioeconomic factors in the Kentucky Medicaid population. The Appalachian region leads the rest of
the state in use of both classes of drugs which might be indicative of the prevalence of chronic
conditions in that region of the state which is known to have high prevalence of diseases as
indicated by low ranks in national health indices (CDC, 2005-2010).
This chapter also described the reasoning for some of the methods in the study. Specifically,
it explains the changes in the Medicare program that led to patients being censored at 65 years.
It also explained the concept of churning in claims data and how that was handled for this study.
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For this study, consecutive segments with no gaps were combined and overlapping segments
were also combined to form one continuous segment.
Chapter four was a nested case-control study comparing patients exposed to COX-2 drugs to
those exposed to COX-1s for their risk of MI. This study found that even though there was an
increased risk for MI when COX-2s were compared to COX-1s, this risk was not significant. The
unadjusted and adjusted relative risk for MI were 1.116 (0.982, 1.270) and 1.138 (0.983, 1.318)
respectively. This sheds some light on the question as to a class effect with regards to risk of MI
from exposure to NSAIDs.
While there was no significant overall class effect, it was found that there was a difference
in risk when the same model was considered for the different age at initiation groups. Patients
in the 30-40 year old group presented a significant increased risk for MI when COX-2 users were
compared to COX-1 users. The unadjusted and adjusted risk estimates were 1.657 (1.201, 2.285)
and 1.600 (1.082, 2.367) respectively. This was the only age group that showed a significant
increased risk. Additionally, this chapter considered switching between the classes of
medication as most of the cohort had switched. It found that patients who were in the two
possible switch groups (COX-1-2 and COX-2-1) did not have a significantly increased risk for MI
when compared to those who had only taken COX-1s. This may be due to an interaction effect
that is not allowing the mechanism to act in favor of one NSAID or the other. However, patients
in the COX-2 only group had a marginally significant increased risk for MI when compared with
those in the COX-1 only group. The unadjusted and adjusted risks were 1.208 (1.014, 1.438) and
1.221 (1.003, 1.485) respectively. This increased risk is clinically important.
Chapter five was also a nested case-control study comparing patients exposed to
meloxicam, a drug for which there is ambiguity in its classification and much less studied,
celecoxib, the only coxib presently on the US market, and naproxen to no exposure for risk of
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MI. Naproxen is a certified COX-1 and celecoxib is a certified COX-2. It was found that risk for MI
for meloxicam was lower than celecoxib and naproxen when the three were compared to no
exposure and accounting for risk factors. The unadjusted and adjusted risk for MI when
meloxicam was compared to no exposure were 1.10 (0.88, 1.38) and 1.26 (0.98, 1.63)
respectively. Two other studies comparing meloxicam with no use have found no significant
increased risk for MI (Garcia Rodriguez et al., 2004; Levesque et al., 2005). There is an apparent
hierarchy in risk with celecoxib showing the most risk followed by naproxen and then
meloxicam. In both the adjusted and unadjusted analysis, meloxicam was not significantly
different from no use with regards to risk for MI but celecoxib and naproxen were.
While this is an observational study and not conclusive, it suggests that meloxicam is
similar to COX-1s than COX-2s as it is similar to naproxen than celecoxib. Even if it is a COX-2
inhibitor it can be considered a safe one.
There are several biases inherent in this study. These include but are not limited to the large
number of patients excluded from the study due to the incorporation of the new users design
and the degree of naiveness of the new users. There are potential cases that could have been
missed in the patients excluded. However, if they had been included in the study it would make
collection of baseline covariates burdensome.
Implications
The results from this study have major implications for patients taking NSAIDs as well as
for public health efforts, given the prevalence of NSAID use in the population. The results found
that there is not a significant overall class difference between COX-1s and COX-2s. Though not
significant the risk is increased. However, there was a significant increased risk for MI for those
taking COX-2s when compared to COX-1s in the youngest age group (30-40 years) and when
COX-2 only users were compared to COX-1 only users. The increased risk for MI is of clinical
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significance; at least for the youngest age at initiation group and the patients who were only
exposed to COX-2s. Clinical consideration should be made by doctors and other health care
providers in the prescription of NSAIDs and subsequent monitoring of said prescriptions;
especially to certain groups of people. This potential increased risk has significant public health
implications especially considering that cardiovascular disease is the leading cause of death
worldwide. Given the seriousness of cardiovascular diseases as a leading cause of death
worldwide, anything that exacerbates that risk is of considerable public health importance. As a
result, the increased risk seen in this study exacerbates the risk for cardiovascular diseases and
thus has considerable public health implications.
Additionally, in this population region which was included in the study as a proxy socioeconomic indicator was significantly associated with MI taking into consideration exposure and
other risk factors. The MI risk with exposure to NSAIDs varies across the state and is higher in
the Appalachian region. From a Kentucky perspective, extra efforts should be put in place to
monitor the NSAIDs-MI association in the Appalachian region which is significantly associated
with risk of MI. Low socio-economic status has been identified as a risk factor for cardiovascular
diseases and the significance of region points to that (Rugg et al., 2008).
In chapter five, both an increased and a significant risk for MI were found when
celecoxib and naproxen were compared to no exposure. However, meloxicam was not
significantly different from no exposure in terms of MI risk in both the unadjusted and adjusted
analysis. There is a slight increased risk for MI but it was not statistically significant. In the
literature, all NSAIDs have been shown to have increased risk for cardiovascular events when
compared to no NSAID use. Since all these medications are still being marketed and used, their
ongoing monitoring with regards to the risk for MI is important. Particularly, increased
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monitoring should be implemented for those in the Appalachian region who are chronic users of
these drugs.
If ignored there could be potential economic consequences associated with health costs
and lost productivity due to illness. Especially considering that the highest risks were seen in the
youngest age group in the cohort.
Strength and Limitations
A major strength of this study was the comparatively longer study period with recent
data. This study had a recent 12 year window of data. The average length of follow-up for this
study was 3.9 years, which allowed for evaluation of both short and long term risks associated
with exposure to NSAIDs. Additionally, this study provides an update on the NSAIDs-MI
association. To our knowledge this is one of the longest study periods in the study of the NSAIDMI association. The large cohort obtained from an electronic database can be considered a
strength as it allows for adequate control of confounding.
Secondly, this study investigated the NSAIDs-MI association in a younger post-market
cohort from a population with a high prevalence of cardiovascular diseases. This allowed for the
incorporation of patient medication adherence behavior into the analysis of the NSAIDs-MI
association. This study takes into consideration patient behavior in determining continuous use
and also accounts for switching which is a common phenomenon in the general population.
Patients switch between medications for many different reasons.
Thirdly, this study was able to assess the MI risk of meloxicam which has been less
studied in the literature. This was made possible because of increased use in this cohort. One of
the reasons why it had not been studied much in the past was lack of sufficient use.
A major limitation of this study was the lack of information on important confounders
associated with the NSAIDs-MI study. This study lacked information on OTC medication, smoking
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and BMI. Some of the medications in this study, like meloxicam and ibuprofen, are available
OTC. The small amount of copay involved with this program serves as an incentive for patients
to maximize its use. As a result, it is hoped OTC medications will not affect the results
significantly. Smoking is important in studies of this kind as it has been identified as a potential
lifestyle confounder. To account for the lack of information on smoking, COPD was used as a
proxy. Additionally, hypertension and angina were accounted for in the analysis and they have
been identified as significantly affected by smoking (Ray, Stein, Hall, et al., 2002). BMI was
another important confounder that was missing in this study. Given its prevalence in the state of
Kentucky it is highly unlikely that it will be differentially distributed between patients who are
exposed to different types of NSAIDs.
However, the lack of information on important confounders is a limitation that is
common to most US studies using electronic databases in this area of research. Their European
counterparts tend to do a better job in capturing such information in electronic databases. For
example, the General Practice Research Database (GPRD) (now known as Clinical Practice
Research Datalink (CPRD)) in the United Kingdom has the most comprehensive longitudinal
patient level data (Lawson, Sherman, & Hollowell, 1998).
Additionally, several studies using administrative databases to assess the NSAIDs-MI
association have employed different methods to account for these limitations (Graham et al.,
2005; S. E. Kimmel et al., 2004) . Graham et al conducted a telephone survey and found the
missing factors were not differentially distributed by NSAID use. In a nation-wide in-home
survey of Medicare beneficiaries using different NSAIDs, they did not differ by BMI and smoking
behavior (Daniel H Solomon et al., 2004). Therefore, in studies which did not measure these
potential confounders, it is likely they were non-differentially distributed across exposure
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groups. Their impact on the study is likely to be minimal and biased the study results towards
the null or no-effect hypothesis (Ray, Stein, Hall, et al., 2002; Daniel H Solomon et al., 2004).
Another limitation is the use of electronic database to define both exposure and
outcome. This could lead to possible misclassification of both. Administrative databases suffer
from miscoding in the form of under-coding. This is usually done at the discretion of health care
providers for various reasons. Due to the seriousness of the outcome, it is highly unlikely that it
will be missed by a health care provider at the hospital due to its seriousness. However, there is
still the likelihood of a silent MI as they are higher in patients with cardiovascular risk factors
(Valensi, Lorgis, & Cottin, 2011). Additionally, due to the economic incentive of having very low
copayments, the misclassification of exposure will be small as most low income patients will
utilize a $1 copay program rather than go out and buy medications on their own. Though very
much minimized, there is still the possibility of misclassification of both the exposure and the
outcome. Additionally, this study only used MI cases that had been admitted to a hospital.
Missing cases due to silent MIs and sudden death would have resulted in incomplete case
identification. Also, there is the possibility that a patient sustained an MI during hospital
admission in which case it will not be included in the admission charts. However, the algorithm
used for identification of the outcome has been validated for use in such scenarios. It was found
to have high sensitivity, specificity and positive predictive value.
There are several challenges involved in using electronic databases for the purposes of
research. Specifically, the conversion of the database from raw files to analysis datasets can be
very cumbersome and involve some resources for adequate management. There are several
things to watch out for. Adequate secure storage space and data management are
fundamentally important to undertake the task to convert raw electronic flat files to analysis
datasets, as was undertaken for this study. Last but not least, security is of utmost importance
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given the nature of the dataset. In short one would need sufficient coding experience, and a
large and secure enough location to store the dataset.
Future Research
The NSAIDs-MI association should be given major attention by healthcare practitioners
especially in light of present health care laws in the US. Continuous monitoring should happen
to see the trends in this association and to keep the risk in check. More so as more people have
access to health care and there is increased use of this class of drugs.
One possible area of future research is to increase the quality of data contained in
publicly available electronic databases. The lack of information on important lifestyle
confounders like smoking and BMI is a major limitation on their use. With the implementation of
a national health insurance program and projected increased use of the healthcare system,
researchers can increase efforts for electronic claims databases to contain such comprehensive
patient level information which will make future research involving these variables more
meaningful. Additionally, this will allow for comprehensive data patients over the whole age
spectrum and the overall effect of these medications can be investigated in the entire
population as opposed to different sections depending on what the choice of electronic data
source allows.
This dissertation used data from the Kentucky Medicaid database which is comprised
mostly of low income patients. Therefore, the results might not be generalizable to the general
population exposed to NSAIDs. Future studies investigating NSAIDs exposure should consider a
broader population within states and nationally. A national database with comprehensive
patient level data will be very instrumental in such research. Collaboration between researchers
and clinicians for future studies will greatly aid this effort.
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Another area of research is an investigation of the switching patterns between different
classes of NSAIDs by patients and the possible ramifications. This study took switching pattern
into consideration and found that risk for MI varied by the kind of switch that was done by the
patients.
The NSAIDs-MI association should remain an important priority for health care
practitioners and public health professionals as continuous monitoring will help reduce the
associated risks for MI which in turn will potentially reduce cardiovascular risk as a result of
exposure to NSAIDs.
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